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     In the late 1980’s, Eli Lilly and Company published a report detailing the 
efforts to synthesize new fluorinated nucleoside analogs to discover agents with 
unique biological activity 1.  Several fluorinated compounds were generated using 
2-deoxy-2,2-difluoro-D-ribose as a backbone.  By replacing a hydrogen atom with 
a fluorine atom in a metabolite, a compound with new biological activity and with 
similar substrate activity may be created since the van der Waals radius of 
fluorine (1.35 Å) is similar to that of hydrogen (1.20 Å) 2, while the 
electronegativity of fluorine (χ = 4.1) is much greater than that of hydrogen (χ = 
2.2) 3.  Nucleoside analogs with substitutions of fluorine atoms at the C2’ position 
have been demonstrated to increase the stability of the glycosidic bond and 
prevent its enzymatic cleavage 4,5.  2-deoxy-2,2,-difluoro-D-ribose was used as 
the main building block for a series of nucleoside analogs in a program focused 
on identifying new antitumor agents.  Several compounds were created during 
this study, with the most promising being 2’,2’-difluoro-2’-deoxycytidine 
(gemcitabine, dFdCyd1, Gemzar), which will be the subject of this dissertation 
(Fig. 1.1)     After synthesis, dFdCyd was shown to have better activity than 
cytosine arabinoside (1--D-arabinofuranosylcytosine, AraC), an anticancer 















Figure 1.1.   Structures of deoxycytidine and gemcitabine.
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dFdCyd has been examined in numerous cell lines and cancer models by a 
number of research groups since its synthesis in 1988.  It was approved by the 
Food and Drug Administration in 1996 for the treatment of advanced pancreatic 
cancer, unique in that it was based mostly on quality of life improvement 7, 
although dFdCyd did provide a small but significant increase in survival 
compared to the standard treatment with 5-fluorouracil 8.  In addition, dFdCyd is 
also approved for treating locally advanced or metastatic non-small cell lung 
cancer, breast cancer, and ovarian cancer 9.   
     In addition to its use in a chemotherapeutic regimen, dFdCyd can also 
enhance cell death induced by ionizing radiation, a process known as 
radiosensitization 10,11.  Radiosensitization is defined as synergistic cell killing 
achieved when a chemotherapeutic and ionizing radiation combine to produce a 
greater than additive cytotoxic effect.  This could be a powerful treatment 
modality, since low, non-cytotoxic concentrations of dFdCyd can produce 
excellent radiosensitization.  Clinical trials with dFdCyd and concurrent radiation 
have produced promising results.  In a University of Michigan study, weekly 
dFdCyd at < one-fourth of a standard chemotherapeutic dose produced excellent 
enhancement of standard radiotherapy-induced cell killing, with nearly 80 % of 
patients achieving a complete pathologic regression of their tumor compared to 
the expected 30-40 % with radiotherapy alone 12.  However, issues did arise with 
toxicity to normal tissue.  The combination of dFdCyd and radiotherapy has also 
been active in patients with pancreatic cancer given either at low dose 13,14 or full 
dose with titration of radiotherapy with acceptable toxicity 15. 
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     To maximize the antitumor activity of dFdCyd and radiation while controlling 
normal tissue toxicity, a greater understanding of the factors that contribute to 
radiosensitization is necessary.  This dissertation will evaluate the roles of p53, a 
cell cycle protein induced by DNA damaging agents such as dFdCyd and 
radiation; ribonucleotide reductase, an important cellular target of dFdCyd; and 
p53R2, a novel ribonucleotide reductase subunit, in the radiosensitizing 
mechanism of dFdCyd.  The introductory chapter of this dissertation examines 
dFdCyd in great detail by describing its metabolism, cytotoxicity, and 
radiosensitization.  The introduction will also describe ribonucleotide reductase 
and p53R2.  Later chapters examine the roles of p53 and p53R2 expression on 
the cytotoxic and radiosensitizing properties of dFdCyd.   
Mechanism of Action 
     To exert its biologic effects, dFdCyd must be transported into the cell, which 
can be accomplished through either equilibrative (human Equilibrative 
Nucleoside Transporters, hENT, sodium independent) or concentrative (human 
Concentrative Nucleoside Transporters, hCNT, sodium dependent) nucleoside 
transporters: hENT1 (equilibrative sensitive), hENT2 (equilibrative insensitive), 
hCNT1 (concentrative insensitive).  Nucleoside transporters are classified as 
equilibrative or concentrative sensitive based on the effectiveness of 
nitrobenzylthioinosine (NMBPR) inhibition 16.  Nucleoside transporters vary 
greatly in their expression levels, as well as in their ability and capacity to 
transport dFdCyd.  The hENT1 and hCNT1 transporters have been shown to be 

















Another study by Mackey et al demonstrated that the hCNT1 transporter had a 
much higher affinity for dFdCyd, with an apparent Km of 24 M, compared to 
hENT1 (Km = 160 M) and hENT2 (Km = 740 M) 
18.  However, the role of 
hENT1 in dFdCyd transport was solidified by research employing the thymidylate 
synthase inhibitors 5-fluorouracil and raltitrexed 19.   Exposure to either of these 
agents increased the expression of hENT1 in pancreatic cancer cell lines and a 
resulting increase in dFdCyd cytotoxicity, representing a potential therapeutic 
benefit.   
     After transport into the cell, dFdCyd must be activated via phosphorylation 
(Fig 1.2).  dFdCyd is initially phosphorylated by dCK (deoxycytidine kinase) to 
dFdCMP, which is the rate-limiting step of dFdCyd metabolism.  The affinity of 
dCK for dFdCyd (Km = 1.4 M) is similar to that of the endogenous substrate 
dCyd (Km = 3.6 M).  Further sequential phosphorylation by dCMP kinase and 
nucleoside diphosphokinase results in the production of the active metabolites, 
2’, 2’-difluorodeoxycytidine diphosphate (dFdCDP) and 2’, 2’-
difluorodeoxycitydine triphosphates (dFdCTP).  dFdCyd is inactivated via 
deamination in either its unphosphorylated or monophosphorylated forms by 
deoxycytidine deaminase and dCMP deaminase, respectively, resulting in the 
production of dFdUrd and dFdUMP 20,21.   
     dFdCDP is a potent and irreversible inhibitor of ribonucleotide reductase (RR) 
22,23, the enzyme responsible for the conversion of ribonucleoside diphosphates 
to their corresponding deoxyribonucleoside diphosphates, which, after further 
phosphorylation to the corresponding triphosphates, are essential precursors for 
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DNA synthesis.  Inhibition of RR by dFdCDP is considered most important for 
dFdCyd-mediated radiosensitization 24.  dFdCDP was first discovered to inhibit 
ribonucleotide reductase activity in leukemia cells 23.  Further research 
uncovered that dFdCDP was a potent mechanism-based inactivator of 
ribonucleotide reductase with a stoichiometric relationship of 1:1 22,25.  This 
inhibition resulted in depletion of deoxynucleotide triphosphate (dNTP) pools and 
stalled DNA synthesis 23,26.  However, the dNTP most depleted as a result of 
dFdCyd exposure differs in leukemia cells and solid tumor cells.  In leukemic 
cells, dCTP is the most depleted dNTP, whereas dATP exhibits the largest 
decrease in solid tumor cells incubated with dFdCyd 11,23.   
     dFdCTP can inhibit DNA synthesis either through competition with dCTP for 
DNA polymerases or via enhancing the incorporation of dFdCMP into the 
elongating DNA strand 26,27.  The apparent Ki values of dFdCTP for DNA 
polymerases alpha and epsilon were 11.2 M and 14.4 M, respectively 26.  The 
ratios of the apparent Km values for incorporation of dFdCTP and dCTP into DNA 
were 21.8 and 22.9 for DNA polymerases alpha and epsilon, respectively 26.  
dFdCTP is the metabolite responsible for cytotoxicity, and a study by Huang et al 
confirmed that incorporation of dFdCMP into DNA was the lethal event 26.  It has 
been suggested that DNA chain termination contributes to dFdCyd-induced cell 
killing 28.  Although dFdCyd has been reported to be a masked chain terminator 
in in vitro DNA primer extension assays in which a single nucleotide is added 
after dFdCMP 26, this does not appear to be true chain termination, as [3H]-
dFdCyd has been detected in full length DNA in intact cells 29.   
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dFdCyd and Radiation 
     Nucleoside analogs have long been considered attractive agents to combine 
with ionizing radiation for a number of reasons.  As DNA synthesis inhibitors, 
nucleoside analogs potentially could inhibit the repair of DNA damage induced by 
ionizing radiation or potentiate radiation-induced damage such as DNA double 
strand breaks (DSBs).  Since nucleoside analogs are preferentially cytotoxic to 
proliferative cells, they could decrease the number of tumor cells and slow tumor 
repopulation during fractionated radiotherapy.  Tumor shrinkage in turn could 
increase tumor oxygenation and deter the deleterious effects of hypoxia on 
radiation response.  However, unlike other antimetabolite radiosensitizers such 
as 5-fluoro-2’-deoxyuridine (FdUrd) and 5-bromo-2’-deoxyuridine (BrdUrd), 
dFdCyd does not either potentiate radiation-induced DSBs or inhibit their repair 
30,31.   
          Hydroxyurea is a chemotherapeutic agent that has been shown to produce 
radiosensitization as a result of inhibition of ribonucleotide reductase and 
subsequent dNTP pool depletion 32.  As dFdCyd was shown to deplete dATP 
pools in cancer cell lines via ribonucleotide reductase inhibition, it was also 
proposed to be a radiosensitizer 10,11.  After initial studies demonstrating potent 
radiosensitization by dFdCyd in HT-29 colon carcinoma cells 11,33, dFdCyd was 
subsequently determined to be a radiosensitizer in head and neck, pancreatic, 
and breast cancer cell lines 10,31,34,35.   
     Radiosensitization can be calculated in a number of ways both experimentally 
and clinically, one of which being the radiation enhancement ratio, which is 
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calculated by dividing the area under the curve for control cells by that of drug-
treated cells 36.  Since these values are normalized for untreated survival, 
overlapping curves would result in an enhancement ratio of 1.0, which represents 
additivity.  Enhancement ratios > 1.0 represent synergy or radiosensitization, 
whereas values less than 1.0 represent antagonism or radioprotection.  While 
enhancement ratios > 1.0 represent radiosensitization, only values of 1.4 or 
greater are considered clinically significant.  Radiosensitization with dFdCyd 
varies with cell line, drug concentration, and schedule of administration, yet 
radiation enhancement ratios (RER) as high as 3.0 have been reported 37.  A 
major advantage of dFdCyd as a radiosensitizer compared to agents such as 
hydroxyurea is that dFdCyd can induce radiosensitization at concentrations that 
are 1000 fold lower than typical plasma concentrations achieved clinically 38.  
Conversely, hydroxyurea requires concentrations of nearly its maximal tolerated 
dose to produce radiosensitization. 
     Radiosensitization of solid tumor cells has been demonstrated to occur 
optimally when dFdCyd exposure precedes radiation.  Excellent 
radiosensitization has been observed when cells are exposed to dFdCyd for 24 
hr, and immediately irradiated 11.  Other studies have analyzed radiosensitization 
when irradiation does not immediately follow drug exposure, and reported 
lowered radiosensitization 39.  Studies have demonstrated that dFdCTP has a 
long half-life and as a result has extended biological activity 11,30.  Depending on 
the concentration of dFdCyd during incubation, radiosensitization can occur up to 
2 days after drug washout in HT-29 cells 30. 
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      Despite much intense effort, the exact mechanism of dFdCyd-mediated 
radiosensitization has yet to be elucidated.  However, two correlative factors 
have been identified for radiosensitization in solid tumors, dATP depletion and S-
phase accumulation prior to irradiation.  Studies have demonstrated that 
depletion of dATP by at least 80% of control values for at least 4 hr is required for 
radiosensitization 11,24,34,35.  Accumulation of cells in S-phase during dFdCyd 
exposure appears to be required for radiosensitization, as Latz et al 
demonstrated that this is the cell cycle phase most sensitive to radiosensitization 
by dFdCyd 39.  Radiosensitization was reduced in synchronized cells incubated 
with dFdCyd during either G1 or G2/M.  A correlation between S-phase 
accumulation and radiosensitization by dFdCyd has been noted in several 
studies 24,35,40.   
dFdCyd Resistance 
     The inherent or induced resistance of tumors to dFdCyd is a major clinical 
issue. dFdCyd has multiple targets, and up- or down-regulation of these targets 
can confer resistance.  Like other nucleoside analogs, dFdCyd is hydrophilic and 
cannot traverse cell membranes by passive diffusion 16.  Alterations in activity of 
nucleoside transporters have been shown to confer resistance to ara-C in 
leukemia cells 41,42.  BIBW22BS, a highly efficient inhibitor of equilibrate 
nucleoside transport, was found to reduce dFdCyd cytotoxicity by as much as 
100-fold in a variety of cancer cell lines 43.  Mackey et al subsequently 
determined that cells with a nucleoside transport deficiency were highly resistant 
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to dFdCyd 17.  However, other reports have not found a similar relationship 
between nucleoside transport and dFdCyd resistance 19,44,45. 
     Phosphorylation of dFdCyd to dFdCMP by dCK is the rate limiting step in 
dFdCyd activation, consequently giving dCK a pivotal role in dFdCyd resistance.  
In fact, the most frequently described form of acquired dFdCyd resistance in vitro 
is dCK deficiency.  Ruiz van Harparen et al issued the first report describing 
dFdCyd resistance conferred through an alteration in dCK 46.  In this study, 
stepwise exposure to dFdCyd resulted in a 30,000-fold dFdCyd-resistant cell line 
with dCK being undetected by western blotting.  This group and others have 
subsequently described a correlation between intrinsic resistance to dFdCyd and 
dCK deficiency in a panel of solid tumor cell lines 46-49.  The correlation between 
dCK and dFdCyd resistance was strengthened by several studies which 
demonstrated a reversal of dFdCyd resistance by transfection of dCK into dCK-
deficient cell lines in vitro 49 and in vivo 50.   
     In addition to the expression of dCK, regulation of dCK through phosphate 
donors and feedback inhibition can also alter dFdCyd sensitivity.  Shewach et al 
proved that UTP was the most efficient phosphate donor for dCK 51, and other 
groups later found decreased UTP pools in dFdCyd-resistant murine leukemia 
and human ovarian cancer cells 46,52.  dCTP is a feedback inhibitor of dCK 53, and 
increased dCTP pools were found in KB human epidermoid carcinoma cells 
resistant to dFdCyd 48. 
     Another important cellular target of dFdCyd is ribonucleotide reductase, and 
several studies have implicated it as a cause of dFdCyd resistance.  In human 
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K562 cells, a 3-fold increase in RR activity resulted in a 45-fold dFdCyd 
resistance 47.  In KB cells, a 2-fold increase in RR activity resulted in a 10-fold 
increase in dFdCyd resistance 48.  Overexpression of the R2 subunit has been 
implicated as a cause of dFdCyd resistance 54.  Conversely, inhibition of RR 
expression and activity, either by chemotherapeutics 55 or by siRNA silencing 56, 
increased dFdCyd sensitivity in a number of solid tumor cell lines.  Increased 
activity of RR results in increased dNTP pools and this can potentially decrease 
dFdCyd sensitivity through three mechanisms.  Firstly, an increase in dNTPs, 
particularly, dCTP, inhibits dCK activity through feedback inhibition, and this 
could potentially result in decreased dFdCyd phosphorylation and incorporation 
into DNA 6,21,48.  Secondly, dNTPs compete with dFdCTP for incorporation into 
DNA, and increased dNTP pools should decrease dFdCTP incorporation and 
cytotoxicity.  Finally, Plunkett et al have shown that increased dCTP pools 
increased deoxycytidine deaminase activity, and this could serve to reduce 
dFdCyd sensitivity 21.   
     dFdCyd is degraded through a number of enzymes, and alterations in their 
expression and activity can affect dFdCyd sensitivity.  5’-Nucleotidase (5’NT) 
opposes the activity of nucleoside kinases by converting nucleotides back to 
nucleosides.  In dFdCyd-resistant K562 variants, resistance was associated with 
increased 5’NT activity 47.  Also, HEK293 cells overexpressing 5’NT via 
transfection displayed a 22-fold reduction in dFdCyd sensitivity 57.  dFdCyd is 
also degraded via deamination by deoxycytidine deaminase (dCDA) and dCMP-
deaminase.  Most of the evidence suggests that dCDA does not play a major role 
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in intrinsic resistance to dFdCyd, although dCDA up-regulation may be a 
pathway of acquired resistance 58.  Although there have been many studies on 
resistance in dFdCyd in experimental systems, there are not enough data to 
draw conclusions on the mechanism of clinical dFdCyd resistance. 
p53 
     The most frequently mutated gene in cancer cells is the tumor suppressor 
gene TP53, resulting in malfunction of its product, p53 59.  Several lines of 
evidence indicate that p53 has an important role in tumor suppression.  The 
effect of p53 status on the sensitivity of cancer cells to chemotherapeutic agents 
or radiation depends on the dual role of p53 as a guardian of genomic integrity 
and a mediator of cell death 60.   In unstressed cells, p53 is sequestered by 
MDM2 through its N-terminal domain, and this targets p53 for degradation by 
ubiquitination 61,62.  p53 is markedly upregulated after DNA damage and serves 
to block progression through the cell cycle or lead to cell death 63.  The decision 
to save or eliminate cells depends on several factors, including insult, degree of 
damage, and oncogenic status of the cell 64,65. 
     The p53 gene has been mapped to chromosome 17.  p21WAF, whose gene 
product is induced by p53, is a well known inhibitor of G1 cyclin-dependent 
kinases 66.  Following exposure to ionizing radiation, p53 is believed to initiate 
cell cycle arrest at the G1/S border through its interaction with p21WAF.  p53 also 
protects cells through initiation of repair processes such as nucleotide excision 
repair 67 and induce senescence 68.  Conversely, p53 can induce programmed 
cell death following irreparable DNA damage.  p53 is believed to induce 
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apoptosis through induction of genes such as bax 69 and fas 70.  However, 
transactivation-deficient p53 cells can also induce apoptosis, indicating that p53 
can induce apoptosis through transactivation-independent mechanisms as well 
71.  
     dFdCyd, either alone or in combination with other agents, can induce p53 and 
cause cell cycle arrest as a result of DNA damage.  As a result, much work has 
been dedicated to examining the role of p53 in dFdCyd sensitivity, either alone or 
when combined with other modalities.  Following disruption of p53 in RKO cells, 
Chen et al observed a decrease in both dFdCyd sensitivity and apoptosis 
compared to the parental cells 72.  However, radiosensitization was not altered in 
this study.  Galmarini et al described increased sensitivity to dFdCyd in wt p53 
breast cancer cells compared to p53 deficient counterparts 73.  In human bladder 
cell lines, Kielb et al did not observe a difference in dFdCyd sensitivity 74.  In 
radiosensitization studies, Ostruszka et al observed radiosensitization in a mt 
p53 but not a wt p53 glioblastoma cell line 24.  In this study, wt p53 D54 cells 
accumulated in G1 in response to dFdCyd, whereas mt p53 U251 cells 
accumulated in S-phase following dFdCyd addition.  However, other studies did 
not observe a difference in S-phase accumulation and radiosensitization between 
wt p53 and p53-deficient cells 35,75,76.      
Ribonucleotide Reductase 
     As previously mentioned, ribonucleotide reductase is an important cellular 
target of dFdCyd, and is particularly essential in the radiosensitizing mechanism 
of dFdCyd.  Ribonucleotide reductase is the enzyme responsible for the 
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conversion of ribonucleotide diphosphates to their corresponding 
deoxyribonucleotide diphosphates, providing DNA precursors for DNA replication 
and repair 77-80.  This is the rate-limiting step in DNA synthesis, and is the target 
of several anticancer agents such as dFdCyd.  There have been three main 
classes of RR described based on different metal cofactors for the catalytic 
activity 80,81.  Class I enzymes are founds in all eukaryotic organisms, as well as 
some prokaryotes and viruses.  Class I enzymes have been further divided into 
three subcategories (Ia, Ib, Ic) based on polypeptide sequence homology and 
allosteric regulation, with human RR belonging to Class Ia 82,83.  Synthesis of 
deoxyribonucleotides is tightly regulated, as a failure in the control of the 
amounts of dNTPs can lead to genetic abnormalities or cell death.   
     Much of the structure and function studies on class I RRs have been 
performed in E. coli and murine systems.  RR is composed of two subunits, R1 
and R2.  R1 is an 85 kDa protein, and it harbors the active site for substrate 
binding, allosteric regulatory sites, and redox active disulfides which are essential 
for substrate reduction 84-86.  R2 is a 45 kDa protein which houses an oxygen-
linked diferric iron center and the tyrosyl radical that initiates substrate reduction 
77,87.  As a result of these different properties, R1 has been termed the regulatory 
subunit, and R2 has been termed the catalytic subunit 86-88.  Although crystal 
structures for both R1 and R2 have been determined separately, no crystal 
structure of the RR holoenzyme has been elucidated.  It has been proposed that 
Class I RRs exist in a tetrameric holoenzyme with a 22 structure 
87,89.  An 66 
hexamer has also been proposed, and its formation is suggested to occur 
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through binding of ATP to the hexamerization site (H-site) 90,91.  However, this 
finding remains largely controversial.    
     Ribonucleotide reductase activity is controlled through its allosteric and 
regulatory sites 77.  The overall enzyme activity is regulated by binding of ATP 
(stimulation) or dATP (inhibition) to the activity site on R1.  A balanced supply of 
dNTPs is maintained through binding of allosteric effectors (dATP or ATP, TTP, 
dGTP) to the specificity site, also on R1.  Binding of dATP or ATP to the 
specificity site stimulates reduction of CDP and UDP, binding of TTP stimulates 
reduction of GDP, and binding of dGTP stimulates reduction of ADP.   
     RR activity is also controlled through the cell cycle by transcriptional 
mechanisms.  The genes encoding R1 and R2 are located on different 
chromosomes in both human and murine cells 92,93.  R1 levels are constant and 
in excess through the cell cycle in proliferating cells, and it has a half-life of 18-24 
h 94.  Conversely, R2 shows an S-phase specific expression with a half-life of 3-4 
h.  Expression of R2 is detected first in early S-phase, with the protein 
accumulating until it is rapidly degraded in mitosis 95.  R2 degradation has been 
linked to a KEN box in its N-terminal region that is recognized by the Cdh1-
anaphase promoting complex that is activated in mitotic cells 96.  This complex 
targets R2 for degradation via ubiquitination.   
p53R2 
     In 2000, Tanaka et al described the discovery of new p53 target genes 
through the use of differential display methods 97.  In this study, a 5.5 kb 




Fig 1.3.  Proposed Mechanisms of R2 and p53R2 activ ity.  In unstressed 
cells, R2 is activated via S-phase dependent genes, and when paired with R1, 
provides dNTPs for DNA replication.  Following DNA damage, p53R2 is activated 
via p53, and when paired with R1, provides dNTPs for DNA repair.  (Adapted 
from Nature 404 (6773) 42-49 (2000)) 
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expressing cell line that had been established from a p53 mutant parental cell 
line, to 5 mM isopropylthiogalactoside (IPTG).  This transcript was not detected 
following exposure to IPTG in a matching cell line which had mutant p53.  Using 
a 132-kb differential display fragment as a probe to screen a cDNA library, an 
almost complete cDNA sequence consisting of 4,995 nucleotides was obtained.  
This cDNA sequence incorporated an open reading frame encoding a 351-amino 
acid sequence with 80% sequence homology to the human ribonucleotide 
reductase small subunit, R2, as well as significant homology to the yeast small 
subunit counterparts, RNR2, and RNR4.  As a result of this protein being induced 
in a p53-dependent fashion, this protein was termed p53R2 (p53-inducible 
ribonucleotide reductase small subunit 2 homologue).  p53R2 or similar variants 
have been subsequently discovered in mice and A. albopictus mosquito cells 
98,99.  Homology exists throughout the peptide sequences except in the N-
terminal region.  The KEN box that is recognized by Cdh1-anaphase promoting 
complex in R2 is not found in p53R2, and as a result p53R2 can be induced in 
any phase of the cell cycle 96.  p53R2 is activated in a p53-dependent fashion in 
response to DNA damage, and has been suggested to play a role in DNA repair 
through supplying dNTPs (Fig 1.3).  Conversely, R2 expression is linked to E2F 
and is induced only in S-phase cells to provide dNTPs for DNA replication.   
     Since its discovery, the role of p53R2 in ribonucleotide reduction has been 
extensively characterized.  p53R2 was initially found to be induced in response to 
exposure to ionizing radiation or adriamycin in a p53-dependent manner 97.  
Guillet et al later determined that p53R2 formed an active RR complex with R1 in 
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vitro, and that ribonucleotide reductase activity increased in response to UV 
radiation in G0/G1 synchronized cells 100.  Yamaguchi et al examined 
ribonucleotide reductase activity in response to ionizing radiation and found a 
correlation between p53R2 expression and RR activity 101.  In this study, p53R2 
was also shown to accumulate in the nucleus in response to DNA damage.  This 
finding was further strengthened by later work by Xue et al in which p53R2 
dissociated from p53 and translocated from the cytoplasm to the nucleus in 
response to DNA damage, and colocalized with R1 102.  This translocation was 
not observed in p53 mutant cell lines.  Synthetic heptapeptide competition 
assays confirmed that p53R2 and R2 share the same binding site on R1, 
although p53R2 had lowered affinity for R1 and lowered RR activity compared to 
R2 in vitro 103.  When paired with R1, these two subunits have also demonstrated 
differing sensitivities to hydroxyurea and DFO in in vitro systems. 
     In addition to its role in providing dNTPs for DNA repair, p53R2 has other 
roles in protecting cells from damaging insults.  Two different studies in mice 
have confirmed that p53R2-null mice die by 14 weeks of age due to kidney 
failure 99,104.  Since these animals developed normally until they were weaned, it 
was postulated that p53R2 may have a role in combating oxidative stress.  
Subsequent findings have confirmed that p53R2 has redox activity and is 
important in the cellular response to oxidative stress 105.  Interestingly, this redox 
activity is tied to its ribonucleotide reductase activity, as mutation of tyrosyl 
residues essential for ribonucleotide reductase results in ablation of redox 
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activity.  In contrast, R2 was shown to have the opposite effect of promoting 
oxidative stress. 
     Recent findings have described a role for p53R2 in preventing metastasis.  
Immunohistological studies on primary and metastatic colon carcinoma samples 
suggested a negative correlation between p53R2 expression and metastasis 
106,107.  Suppression of p53R2 expression was found to increase both invasion 
and migration.  Conversely, overexpression of p53R2 by gene transfection 
reduced cell invasion potential by as much as 54%.  Increased expression of R2 
was associated positively with metastasis, although the results were not 
statistically significant.   
Dissertation Rationale 
     The purpose of this dissertation was to elucidate the mechanisms by which 
dFdCyd potentiates radiation-induced cell killing.  Much work in this laboratory 
has been dedicated to this endeavor, and we have previously identified dATP 
depletion and S-phase accumulation prior to radiation exposure as correlative 
factors.  Studies undertaken were based on earlier findings in this laboratory and 
others and ideas formulated over the past few years.   
     While there is a considerable literature on the role of p53 in cytotoxicity with 
dFdCyd, there has been less attention directed at understanding the role of p53 
in dFdCyd-mediated radiosensitization 24,35,75.  In particular, work in a pair of 
glioblastoma cell lines, D54 (wt p53) and U251 (mt p53), appeared to indicate a 
role for p53 in radiosensitization 24.  In response to dFdCyd, U251 cells 
accumulated in S-phase and were subsequently radiosensitized, whereas D54 
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cells accumulated in G1 and were not radiosensitized.  Both cell lines were 
depleted of dATP similarly.  It was hypothesized that p53 could prevent or reduce 
radiosensitization clinically by inducing a G1 block and preventing S-phase 
accumulation. 
     Therefore, in the studies presented in Chapter II, we have evaluated the role 
of p53 on the ability of dFdCyd to produce radiosensitization by utilizing a high, 
clinically relevant concentration of dFdCyd in MCF-7 breast carcinoma cells.  It 
was important to determine whether this high concentration of dFdCyd would 
result in a high and rapid induction of p53, and whether this would in turn cause 
cell cycle arrest in G1, thus preventing radiosensitization as cells would not 
accumulate in S-phase.  Although we were able to induce p53 rapidly in 
response to IC90 dFdCyd, we still observed radiosensitization of MCF-7 cells.     
     During the completion of this project, a study describing a p53-inducible 
ribonucleotide reductase subunit was published 97.  Because of the essential role 
of ribonucleotide reductase inhibition in dFdCyd-mediated radiosensitization, it 
was a natural progression to study the potential roles of p53R2 in our 
radiosensitizing model.  Since p53R2 can provide dNTPs in response to DNA 
damage, the potential exists that this activity could work to alter radiosensitization 
through maintenance of dNTP pools. 
      Although studies have evaluated the response of p53R2 to radiation, very 
little had been published examining the induction of p53R2 in response to 
chemotherapeutics.  In addition, most studies that evaluated p53 in response to 
dFdCyd were published before the discovery of p53R2, so it was unclear if 
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dFdCyd exposure resulted in p53R2 expression in wt p53 cell lines.  Therefore, 
in Chapter III we initiated the first study to our knowledge that closely examined 
the kinetics of induction of p53R2 and R2 in response to a chemotherapeutic, 
either used alone or in combination with ionizing radiation.  We hypothesized that 
dFdCyd exposure would result in an upregulation of p53R2 as a result of DNA 
damage, and an upregulation of R2 due to S-phase accumulation.  Conversely, 
we predicted that exposure to ionizing radiation would result in an upregulation of 
p53R2 due to DNA damage and a downregulation of R2 as a result of cells 
progressing out of S-phase and accumulating in G1 and G2/M.  p53R2 
expression was induced within 4 hr of dFdCyd addition in two wt p53 cell lines, 
even at low, non-cytotoxic concentrations.  Expression of p53R2 was also rapidly 
induced in response to ionizing radiation.  p53R2 expression appeared 
unaffected by cell cycle distribution. 
     Chapter III further examines p53R2 by evaluating whether induction of p53R2 
alters radiosensitization.  We utilized two sets of cell lines matched for p53 
status, MCF-7 (wt p53) and MCF/Adr (mt p53) breast carcinoma cells, and 
HCT116 (wt p53) and HCT116p53-/- colon carcinoma cells.  We hypothesized that 
radiosensitization would be greater in cell lines with mutant p53, thus 
theoretically lacking p53R2, than in those with functional p53 and p53R2.  This 
would be due to the activity of p53R2 in perturbing dNTP depletion in response to 
dFdCyd exposure.  However, the two sets of matched cell lines demonstrated 
little difference in radiosensitization.  In addition, no difference in dATP depletion 
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in response to dFdCyd exposure was noted at equitoxic concentrations in the 
matched cell lines.    
     Although the cell lines previously used were matched for p53 status, they 
demonstrated differences in sensitivity to dFdCyd and ionizing radiation as single 
agents.  In addition, these cell lines have been grown separately over several 
years and may have acquired additional differences that may have altered drug 
and/or radiation sensitivity.  As a result Chapter IV further examines the role of 
p53R2 in dFdCyd-mediated radiosensitization by examining the effects of 
suppression of p53R2 on radiosensitization.  This will allow for the determination 
of the effects of p53R2 induction on radiosensitization in a single cell line.  
Initially, MCF-7 breast cancer cells were utilized and the effects of p53R2 
silencing by siRNA were determined.  We predicted that p53R2 silencing would 
increase dFdCyd-mediated radiosensitization as a result of increased dNTP 
depletion.  Although we were able to inhibit dFdCyd-mediated increases in 
p53R2 expression, this suppression did not alter radiosensitization.  We then 
chose a second cell line, the A549 lung carcinoma cell line, and attempted to 
increase radiosensitization by suppression of p53R2.  This cell line was 
previously demonstrated to not be radiosensitized by IC10 dFdCyd, and dATP 
was depleted by 65% of control levels.  Radiosensitization was observed at the 
IC50, and dATP was depleted to >80% of control levels.  This suggested that 
p53R2 may have prevented radiosensitization at low dFdCyd concentrations by 
maintaining dNTP pools.  In this cell line, silencing of p53R2 did result in 
increased radiosensitization.  Nucleotide pool studies demonstrated that 
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silencing of p53R2 resulted in increased dNTP depletion, which may have 
accounted for increased radiosensitization.   
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Footnotes to Chapter I 
 
     1The footnotes used are: dFdCyd, 2’,2’-difluoro-2’-deoxycytidine; dCyd, 
deoxycytidine; dFdCMP, 5’-monophosphate of dFdCyd; dFdCDP, 5’-diphosphate 
of dFdCyd; dFdCTP, 5’-triphosphate of dFdCyd; dNTP, deoxynucleotide 
triphosphate; dFdUrd, 2’,2’-difluoro-2’-deoxyuridine; dFdUMP, 5’-monophosphate 
of dFdUrd, dATP, deoxyadenosine triphosphate, dCTP, deoxycytidine 
triphosphate, TTP, thymidine triphosphate, dGTP, deoxyguanosine triphosphate; 
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THE EFFECTS OF HIGH [dFdCyd] ON p53 EXPRESSION, CEL L CYCLE 





Gemcitabine (2’, 2’-difluorodeoxycytidine, dFdCyd) is a nucleoside analog with 
potent radiosensitizing properties in solid tumor cells in vitro and in vivo.  
Radiosensitization with dFdCyd has correlated with dATP depletion, mediated by 
inhibition of ribonucleotide reductase by dFdCyd diphosphate, and accumulation 
of cells in S-phase.  Although dFdCyd can induce p53, a conclusive role for this 
cell cycle regulatory protein in radiosensitization by dFdCyd has not been 
demonstrated.  Previous studies were performed using low concentrations of 
dFdCyd that induced only low levels of p53.  Using wild-type p53 expressing 
MCF-7 cells, we evaluated the effect of a higher and more clinically relevant 
concentration of dFdCyd to determine whether this would result in higher 
induction of p53, which may prevent S-phase accumulation and 
radiosensitization.  Following a 24 hr exposure to dFdCyd at its IC90, high 
expression of p53 was induced rapidly, and greater than 80% of the cells 
accumulated in S-phase.  While 5 Gy also induced high expression of p53, cells 
accumulated in G1 and G2/M with <10% of cells remaining in S-phase after 24 
hr.  Evaluation of p53 expression in each phase of the cell cycle demonstrated 
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that this cell cycle regulatory protein was induced in S-phase and G2/M cells 
after dFdCyd treatment, whereas radiation induced p53 expression in G1 and 
G2/M, consistent with the observed cell cycle blocks.  The combination of IC90 
dFdCyd followed by ionizing radiation produced an enhancement ratio of 2.7, 
significantly higher than that produced by the IC10 or IC50 of dFdCyd (<1.9).   
Taken together, these results demonstrate that exposure to a high, more 
clinically relevant dose of dFdCyd can result in high and rapid induction of p53 
primarily in S-phase and G2/M cells.  This does not preclude accumulation of 
cells in S-phase and therefore does not prevent dFdCyd-mediated 
radiosensitization.  
Introduction 
     Gemcitabine (dFdCyd, Gemzar) is a nucleoside analogue that has shown 
excellent clinical activity in a variety of solid tumors, including pancreatic 1-4 and 
non-small cell lung cancers 5-10.  In addition to its activity as a chemotherapeutic 
agent, studies have demonstrated that dFdCyd can sensitize cancer cells to the 
cytotoxic effects of ionizing radiation 11-14.  This radiosensitizing effect has been 
demonstrated in cultured cells, and the combination has been shown to be at 
least additive in animal models 15-20.  Preliminary clinical studies indicate that 
dFdCyd can act as a radiosensitizer in patients as well 21-24.   
     In tumor cells, dFdCyd is phosphorylated to two biologically important 
metabolites, dFdCDP and dFdCTP 25.   dFdCDP has been shown to be a potent 
inhibitor of ribonucleotide reductase, and this inhibition results in depletion of 
deoxynucleotides essential for DNA synthesis 25,26.  In solid tumor cells, inhibition 
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of ribonucleotide reductase results in dATP depletion primarily and a slowing of 
DNA synthesis 14,27.  dFdCTP can inhibit DNA synthesis either through 
competition with dCTP for DNA polymerases or via the incorporation of dFdCMP 
into the elongating DNA strand 28,29.  The mechanism for radiosensitization by 
dFdCyd has not yet been fully elucidated.  Many radiosensitizers work through 
increasing radiation-mediated damage or interfering with the rate of DNA repair.  
However, dFdCyd does not increase radiation-induced double strand breaks or 
inhibit their repair 11,30.  Correlative studies have shown that the dFdCDP-
mediated decrease in dATP is important for radiosensitization 11,14,27,31.  Cell 
cycle studies have suggested that S-phase accumulation prior to irradiation is 
important for radiosensitization as well 14,32,33. 
     Previous work from this and other laboratories has evaluated the role of p53 
expression on cytotoxicity and radiosensitization with dFdCyd 34-41.  These 
studies have demonstrated that expression of wild-type p53 can enhance 
cytotoxicity of dFdCyd in some, but not all, cell lines.  A clear role for p53 has not 
been demonstrated in radiosensitization with dFdCyd.   In D54 glioblastoma 
cells, which express wild-type p53, addition of dFdCyd at the IC50 did not allow 
accumulation of cells in S-phase, and these cells were not radiosensitized by 
dFdCyd.  Evaluation of isogenic MCF-7 cell lines expressing either wild-type or 
mutant p53 demonstrated that both cell lines were equally well radiosensitized by 
dFdCyd at non-cytotoxic or moderately cytotoxic (IC50) concentrations 
40.  Chen 
et al used matched RKO colorectal carcinoma cell lines that were p53 wild-type 
or null and reported that neither cell line could be radiosensitized with dFdCyd 34.  
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The latter two studies demonstrated that, under conditions in which dFdCyd 
treatment induced p53 expression, it did not alter S-phase accumulation prior to 
irradiation or subsequent radiosensitization.  However, these studies were 
carried out using concentrations of dFdCyd ranging from 10 to 80 nM, far lower 
than the typical clinically useful doses resulting in plasma levels in the µM range.  
We noted in the MCF-7 cells that 80 nM dFdCyd induced p53 expression slowly, 
requiring approximately 8 hours for maximal expression, and cells were able to 
progress into S-phase during drug incubation.  It was then important to ask 
whether higher concentrations of dFdCyd, more similar to the typical plasma 
levels achieved in patients, would produce a more rapid induction of p53 
expression that may induce a G1 block as observed in D54 cells.  If that 
occurred, we would predict that dFdCyd would not act as a radiosensitizer.  The 
studies presented here have evaluated a high concentration of dFdCyd (IC90) 
which promotes a more rapid and higher induction of p53 compared to dFdCyd at 
its IC10 and IC50, and then assessed subsequent effects of high dose dFdCyd on 
cell cycle progression and radiosensitization.  A preliminary account of these 
findings has been reported previously in abstract form 42. 
Materials and Methods 
Cell Culture and Drug Preparation.   The MCF-7 breast carcinoma cells were 
cultured in RPMI medium (GIBCO Laboratories, Grand Island, NY), 
supplemented with 10% calf serum (GIBCO), and 2 mM L-glutamine (Fisher 
Scientific, Fair Lawn, NJ).  Cells were maintained in logarithmic growth as a 
monolayer in T75 culture flasks at 37°C in a humidi fied atmosphere containing 
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5% CO2.  Gemcitabine was a generous gift from Eli Lilly and Co. (Indianapolis, 
IN), which was dissolved in PBS to obtain a stock solution of 10 mM and 
sterilized before diluting further with PBS to achieve final concentrations of 1, 10, 
and 100 µM. 
Cell Survival Assay.   Cells were assayed for clonogenic survival as described 
previously 14.  Briefly, cells were plated in T25 culture flasks at a concentration of 
200,000 cells per flask and allowed to grow for approximately two days.  After 
treatment with dFdCyd and/or ionizing irradiation, cells were reseeded at known 
densities and allowed to grow for 10-14 days and colonies were stained with 
crystal violet.  Cell survival was expressed as a percentage of the control 
survival, after correcting for plating efficiency.  Radiation survival data from 
dFdCyd-treated cells were corrected for plating efficiency using an unirradiated 
plate treated with dFdCyd under the same conditions.  Cell survival curves were 
fit using a linear-quadratic equation 43.  Radiation sensitivity is expressed in terms 
of the mean inactivation dose, which represents the area under the cell survival 
curve.   Radiosensitization is expressed as an enhancement ratio, which is 
defined as the mean inactivation dose (control)/mean inactivation dose (dFdCyd). 
Irradiation of Cells.   Monolayer cultures of cells were irradiated using Co60 
(AECL Theratron 80) at 1-2 Gy/min.  Dosimetry was carried out using an ionizing 
chamber connected to an electrometer system that was directly traceable to a 
National Institute of Standards and Technology standard.  All cells were 
irradiated at room temperature.                                                                  
Western Blot Analysis.  After harvesting, cell pellets were incubated with 50 µl 
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lysis buffer, vortexed, and centrifuged.  The supernatant was used for analysis 
after determination of protein concentration with a Bio-Rad (Bio-Rad 
Laboratories, Hercules, CA) protein assay.  For each sample, 50 µg protein was 
loaded onto a 10% polyacrylamide gel.  After electrophoresis for 2 hours at 150 
V, the protein was transferred onto Immobilon-P transfer membrane (Millipore 
Corp., Bedford, MA) for 2 hours at 125 mA.  The membranes were incubated 
overnight with a 5% milk solution at 4°C to block n on-specific binding sites.  The 
membrane was then incubated with a 1:500 dilution of p53 (Ab-6) monoclonal 
mouse IgG antibody (Calbiochem) for 2 hours followed by incubation with a 
1:20000 dilution of secondary anti-mouse IgG horseradish peroxidase linked 
antibody for 1 hour at room temperature.  After the primary and secondary 
antibody incubations, the membranes were washed with Tris-buffered saline with 
0.1% Tween-20 three times for 15 minutes each.  Proteins that bound the 
antibodies were visualized using an enhanced chemiluminescence detection 
system (Pierce, Rockford, IL). 
Flow Cytometry Analysis.  Control or drug-treated cells were incubated in the 
dark with 30 µM bromodeoxyuridine (BrdUrd) for 15 minutes prior to the 
conclusion of the dFdCyd incubation period or for 15 minutes prior to irradiation, 
and processed as described previously 44.  Briefly, following BrdUrd exposure, 
cells were harvested, fixed in ethanol and stored at 4oC.  On the day of analysis, 
cells were incubated with PBS containing 0.5 mg/ml RNase A (Boerhinger-
Mannheim, Germany) and centrifuged, followed by 0.1 N HCl containing 0.7% 
Triton-X 100 (Sigma Chemical Co.).  Following centrifugation, cells were 
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suspended in HPLC water and centrifuged.  The supernatant was removed and 
cell pellets were incubated with a mouse anti-BrdUrd (PharMingen, San Diego, 
CA) or anti-p53 (Calbiochem) antibody, followed by a FITC-conjugated goat anti-
mouse antibody (Sigma).  After centrifugation, cells were resuspended in 0.5 ml 
propidium iodide (18 µg propidium iodide (Sigma), 40 mg RNAse A/ml) in PBS 
then analyzed with the Coulter (Beckman Coulter, Fullerton, CA) EPICS Elite 
flow cytometer by the University of Michigan Biomedical Research Core Facilities 
Flow Laboratory. 
Results 
Effect of dFdCyd on p53 Expression 
     Previously, we demonstrated that dFdCyd at its IC10 poorly induced p53 
expression in MCF-7 cells, however higher p53 expression was induced by IC50 
dFdCyd and 5 Gy irradiation 40.  In the current study, MCF-7 cells were incubated 
for 24 hr with dFdCyd at its IC10 (10 nM), IC50 (80 nM), or IC90 (300 nM) and p53 
expression was evaluated periodically.  Using Western blot analysis, an increase 
in p53 expression was evident within 2 h of exposure to the IC50 for dFdCyd, and 
p53 expression remained elevated for the remained of the drug exposure period 
(Fig 2.1).  Conversely, p53 expression did not increase until 8 hr after drug 
addition at the IC10 of dFdCyd.  Incubation with the IC90 for dFdCyd resulted in a 
larger and more rapid increase in p53 expression compared to IC50 treatment.  
Treatment with 5 Gy also resulted in a rapid and substantial increase in p53 
expression within 2 h after irradiation, and remained elevated throughout the 24 














Figure 2.1.  Effect of dFdCyd or radiation on p53 e xpression .  Western blots 
were performed in MCF-7 cells treated with either dFdCyd at its A) IC10, B) IC50, 
C)IC90, or D) 5 Gy irradiation. Cells were harvested at times indicated and 
analyzed via Western blotting as described in “Materials and Methods.” 
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determine the effect of high and rapid induction of p53 on cell cycle progression 
and radiosensitization with dFdCyd.   
Cell Cycle Analysis 
     Dual parameter (PI/BrdUrd) flow cytometry was used to evaluate the effect of 
the IC90 of dFdCyd on cell cycle progression.  Following addition of 300 nM 
dFdCyd, there was a steady accumulation of cells into S phase throughout the 
incubation period, while the percentage of cells in G1 and G2/M phases 
decreased (Fig 2.2A, Table 2.1).  By 24 h after dFdCyd addition, greater than 
80% of the MCF-7 cells had accumulated in S-phase.  As expected, this highly 
cytotoxic concentration of dFdCyd resulted in a profound decrease in DNA 
synthesis as evidenced by a decrease in BrdUrd incorporation to less than 20% 
of control levels by 4 hr after dFdCyd addition (Fig. 2.2A).  Cell number remained 
constant over this time period, consistent with the inhibition of DNA synthesis.  
Following dFdCyd washout, cells began to progress through S-phase and then 
into G2/M and G1, as evidenced by the flow cytometry results and 70% increase 
in cell number 24 hr post-washout.   
     In contrast to the results with dFdCyd, treatment with 5 Gy resulted in a 
decrease in the S-phase population, with accumulation of MCF-7 cells in G2/M 
and G1.  The S-phase population began to decrease within 4 hr after irradiation, 
declining to <5% by 24 hr post irradiation (Fig. 2.2A, Table 2.1).  Both G1 and 
G2/M populations increased after irradiation, with approximately 47 % of cells in 
G1 and 30% of cells in G2/M by 24 hr post-irradiation.  Cells appeared to 





Figure 2.2.  Effect of IC 90 dFdCyd and/or 5 Gy Ionizing Irradiation on Cell 
Cycle Distribution. MCF-7 cells were either incubated for up to 24 hr with 300 
nM dFdCyd, exposed to 5 Gy ionizing radiation, or dFdCyd for 24 hr followed by 
irradiation, then assayed for cell cycle distribution using dual parameter flow 
cytometry.  Histograms shown are from times A) during dFdCyd incubation or B) 
following washout.  Times represent hours after exposure to dFdCyd or 
irradiation.  The X-axis represents increasing PI incorporation, and the Y-axis 
represents increasing BrdUrd incorporation. 
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IC90 dFdCyd 
                                                                                                                           
Time (hr)        G1                 S                 G2/M                A                    SNI 
0                    37.5           35.0   8.3            10.2                  9.0 
2                    54.2           38.5   5.5            0.8                    0.9 
4                    44.6           50.3   2.2            1.9                    1.0               
8             22.7           71.7   0.4            4.4                    0.4 
24             7.0           84.3   0.2            6.9                    1.4          
 
      5 Gy 
_________________________________________________________ 
Time (hr) G1  S  G2/M   A  SNI 
0             35.0           49.6   10.6            3.4             4.1 
2             32.0           48.5   13.9            3.5             2.1 
4             41.1           22.3   22.3            5.0             9.4 
8             43.5           19.2   25.5            2.7             9.2 
24             47.5              4.5    29.8            2.2             5.9              
 
Table 2.1.  Cell Cycle Distribution of MCF-7 Cells During Exposure to 
dFdCyd or Ionizing Radiation.   MCF-7 cells were either incubated for up to 24 
hr with 300 nM dFdCyd or exposed to 5 Gy ionizing radiation, then assayed for 
cell cycle distribution using dual parameter flow cytometry.  Time 0 hr represents 
the time of addition of dFdCyd or exposure to radiation.   
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IC90 
                 
Time (hr) G1  S  G2/M   A  SNI 
24   37.6           43.1    3.9  10.7  4.6 
48   42.4           30.3    3.2  14.1  10.1  
 
5 Gy 
            
Time (hr) G1  S  G2/M   A  SNI 
24   64.8           8.5   10.7  7.8  5.0 
48   56.7           15.3   15.5  5.3  4.9  
   
IC90/5Gy 
            
Time (hr) G1  S  G2/M   A  SNI 
24   11.0           77.7    1.8  6.4  3.1 
48   22.6           53.4    6.4  14.0  3.6  
 
Table 2.2.  Cell Cycle Distribution of MCF-7 Cells Following  a 24 hr 
Exposure to dFdCyd and/or Ionizing Radiation.   MCF-7 cells were incubated 
with 300 nM dFdCyd for 24 h and/or irradiated with 5 Gy ionizing radiation, then 
assayed for cell cycle distribution using dual parameter flow cytometry.  Times 
indicate hours following drug removal.   
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percentage of cells in G2/M while cells in G1 and S-phase increased (Fig 2.2B, 
Table 2.2).  Cell number also increased by 60% at 48 h post-irradiation, 
indicating that cells were actively dividing at this timepoint.  However, cells did 
not return to a normal cell cycle distribution pattern for at least 72 hr after 
irradiation (Fig. 2.2B, data not shown).  After cells were incubated with dFdCyd at 
its IC90 for 24 h followed by irradiation with 5 Gy, the cell cycle distribution pattern 
was similar to that observed with dFdCyd alone (Fig. 2B, Table 3).  Greater than 
75% of the cells remained in S-phase for at least 24 h after drug washout.  
Although the G1 and G2/M populations began to increase at 48 hr post-washout, 
their percentages remained below those observed in untreated cells.     
     After exposure to dFdCyd or 5 Gy alone or in combination, there was no 
significant increase in the apoptotic population throughout the time course 
studied.  However, the SNI population (cells with S-phase DNA content but not 
incorporating BrdUrd) appeared to increase somewhat after 24 hr in cells that 
were irradiated compared to controls.   
Radiosensitization 
    After observing that the IC90 of dFdCyd elevated p53 expression but did not 
prevent cells from accumulating in S-phase, the ability of this concentration of 
dFdCyd to radiosensitize MCF-7 cells was determined.   In previous studies, 
MCF-7 cells were radiosensitized at IC10 and IC50 concentrations, with radiation 
enhancement ratios (RER) of 1.9 + 0.1 and 1.7 + 0.3, respectively 40.  Radiation 
sensitivity was greatly enhanced with IC90 dFdCyd, with an RER value of 2.7 + 
0.1, a marked increase over that observed at either the IC10 or IC50. 
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Cell Cycle Dependent p53 Expression 
     Since treatment of MCF-7 cells with either the IC90 for dFdCyd or 5 Gy 
radiation induced a similar pattern of p53 expression but resulted in drastically 
different cell cycle distribution patterns, we wished to determine whether there 
was a difference in the phase of the cell cycle in which p53 was induced with 
these treatments.  For this study, a two-parameter flow cytometric procedure was 
used in which MCF-7 cells were stained with PI to determine cell cycle position, 
and p53 expression was measured by antibody fluorescence.  Using this 
technique, a low level of p53 expression was observed in most cells in the 
absence of radiation or drug treatment (data not shown).  Therefore, we 
expressed the results as the -fold increase in p53 expression in cells in each cell 
cycle phase after dFdCyd addition or irradiation compared to control untreated 
cells.  Incubation with dFdCyd at its IC90 resulted in increases in p53 expression 
in all three cell cycle phases (Table 3.3).  Increased p53 expression was 
detected as early as 4 h after dFdCyd addition, and it remained elevated for the 
remainder of the incubation. In contrast, treatment with ionizing irradiation 
resulted in increases in p53 expression primarily in G1 and G2/M.  Induction of 
p53 in G1 cells was evident within 2 hr after irradiation, and an elevated level of 
p53 was sustained for at least 24 hr.  Increases in p53 expression in G2/M were 
less dramatic and appeared to decrease after 2 hr, while only minimal changes 






Time (hr) G1   S   G2/M 
0  1   1   1 
2  1.1   1.1   1.2 
4  1.6   1.4   1.6 
8  1.5   1.5   1.5 




Time (hr) G1   S   G2/M 
0  1   1   1 
2  2.0   1.1   1.6 
4  1.9   1.1   1.2 
8  1.6   0.9   0.9 
24  1.7   0.9   1.4 
 
Table 2.3.  Fold Increase in p53 Expression Followi ng Exposure to 300 nM 
dFdCyd or 5 Gy Ionizing Irradiation .  MCF-7 cells were treated with either 300 
nM dFdCyd for up to 24 hr or exposed to 5 Gy irradiation.  At the timepoints 
indicated, cells were harvested and assayed as described in Materials and 
Methods.  Results are shown as the fold increase in p53 expression compared to 
control untreated cells.   
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Discussion  
     The tumor suppressor protein, p53, is induced following exposure to a variety 
of DNA damaging agents, including chemotherapy drugs and ionizing radiation.  
Expression of p53 following DNA damage results in a series of events that may 
lead to a G1 or G2 cell cycle arrest, or apoptosis 45.  While previous studies have 
not demonstrated a conclusive role for p53 in radiosensitization with dFdCyd, 
those studies used moderate doses of dFdCyd that induced low or a slow 
increase in expression of p53 34-41.  Here we wished to determine whether a 
higher, more clinically relevant concentration of dFdCyd would result in greater 
induction of p53 and, consequently, prevent the S-phase accumulation that 
appears to be required for radiosensitization.  The results demonstrated that a 
highly cytotoxic dose of dFdCyd induced p53 in S-phase cells in a time-
dependent manner. However, the rapid induction of p53 following dFdCyd 
addition did not prevent S-phase accumulation, and therefore treatment with 
ionizing radiation after dFdCyd produced excellent radiosensitization. 
 The results demonstrated that the IC90 for dFdCyd induced higher levels of 
p53 compared to the IC10 or IC50 for dFdCyd.  In the presence of the rapid and 
high induction of p53 and strong inhibition of DNA synthesis, cells readily 
progressed into S-phase at the IC90.  These results are similar to those observed 
at lower concentrations of dFdCyd in MCF-7 and other cell lines 34,40 but different 
from the wild-type p53 expressing D54 glioblastoma cells which exhibited a G1 
block after dFdCyd exposure 33.  The mounting evidence indicates that p53 
expression does not produce G1 accumulation following dFdCyd exposure, and 
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the results observed in the D54 cell line appear to be unique to that particular cell 
line.   
      The increase in p53 expression in S-phase cells following dFdCyd exposure 
likely reflects the two major cellular effects of dFdCyd on DNA replication.  
dFdCTP can inhibit replicative DNA polymerases, and its incorporation into DNA 
has been correlated with cytotoxicity 28; both are events which may induce p53.  
In addition, inhibition of ribonucleotide reductase results in dNTP pool depletion 
and cessation of DNA synthesis in S-phase cells.  Since imbalances in dNTP 
pools can lead to misincorporation events in DNA and eventually cell death 46, 
this may also lead to induction of p53.  Thus, there are several mechanisms by 
which dFdCyd can induce p53 in S-phase cells.  The induction of p53 by dFdCyd 
in G1 and G2/M cells is not as clear.  It is possible that some cells were able to 
progress out of S-phase with unrepaired DNA lesions (e.g. mismatched 
nucleotides, dFdCMP in DNA).  If these lesions were detected during G2, this 
may have resulted in induction of p53 in an effort to repair the DNA damage.  
This population may also represent cells in which p53 was induced during S-
phase, and the cells simply progressed into G2/M with elevated p53 levels.  
Although the percentage of cells in G2/M decreased during drug exposure, the 
total number of cells in this cell cycle phase was low and therefore an influx of a 
small number of S-phase cells could have resulted in the increased p53 
expression in G2/M cells.  The slow increase in the percentage of G2/M cells is 
consistent with either of these explanations.  The increase in p53 expression in 
G1 cells is more difficult to reconcile, as it is unlikely that cells progressed from 
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S-phase through G2/M to G1 with elevated p53.  It is most likely that a portion of 
cells detected as G1 cells by this technique are actually early S-phase cells, 
since PI staining cannot distinguish between cells in early S-phase and G1 as 
they have similar DNA content.  Consistent with this idea, the PI/BrdUrd method, 
which determines cell cycle distribution more accurately (Table 1), demonstrated 
a nearly 50% increase in the number of cells in early S-phase by 4 hr after 
dFdCyd addition, the time at which an increase in p53 expression in G1 cells was 
observed.  Thus, we believe it is most likely that the increase in p53 expression 
in G1 cells actually represents p53 induction in early S-phase cells.   
     Whereas dFdCyd induced expression of p53 primarily in S- and G2/M cell 
cycle phases, following ionizing radiation p53 induction was apparent only in G1 
and G2/M.  As S-phase is generally considered the most radioresistant phase, it 
was not surprising to observe little induction of p53 following irradiation.  The 
rapid and high induction of p53 in G1 and G2/M following ionizing radiation is 
consistent with the observed p53-induced blocks in those cell cycle phases.  
     Interestingly, radiosensitization increased dramatically at the IC90 for dFdCyd, 
with an enhancement ratio of 2.7 compared to the enhancement ratios of <1.9 
observed at the IC10 and IC50 
40.  We have demonstrated previously that 
radiosensitization with dFdCyd correlates with depletion of dATP pools and 
accumulation of cells in S-phase, but not with incorporation of dFdCMP into DNA.  
At the IC50 for dFdCyd, dATP was depleted >80% within 2 hr after drug addition 
and decreased to undetectable levels for the remainder of the 24 hr incubation.  
Thus, dATP depletion would be at least as great at the IC90.  Accumulation of 
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cells in S-phase was also similar at the IC50 and IC90 (78% vs. 84%, 
respectively).  An important difference between these drug exposures is the 
persistence of the S-phase accumulation following irradiation.  At the IC50 for 
dFdCyd, cells began to progress through the cell cycle after irradiation, with the 
percentage of cells in S-phase decreasing to 50% and 12% at 24 and 48 hr after 
washout, respectively.  However, at the IC90, cells persisted in S-phase longer, 
with 78% and 53% of cells remaining in S-phase 24 and 48 hr after irradiation, 
respectively.  We have hypothesized that radiosensitization with dFdCyd is due 
to misincorporation events during DNA replication in the presence of low dATP 
pools 47.  Longer persistence of cells in S-phase with low dATP pools while DNA 
was slowly replicating would likely result in a greater number of misincorporation 
events and thus greater radiosensitization, as we have observed with dFdCyd at 
the IC90.   
     The results presented here demonstrate that high dose dFdCyd induced rapid 
and high induction of p53 primarily in S-phase and G2/M, and thus did not 
prevent S-phase accumulation or radiosensitization.  Furthermore, 
radiosensitization increased in MCF-7 cells with the higher and more 
physiologically relevant IC90 of dFdCyd.  This is an important finding since the 
high concentrations of dFdCyd used in these studies is more similar to that 
achieved in clinical studies combining dFdCyd with radiotherapy 21,23,48.  Our 
results suggest that dFdCyd-mediated radiosensitization, at doses typically used 
in patients, should not be impeded by p53 status. 
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Footnotes to Chapter II 
     1The footnotes used are: dFdCyd, 2’,2’-difluoro-2’-deoxycytidine; dCyd, 
deoxycytidine; dFdCMP, 5’-monophosphate of dFdCyd; dFdCDP, 5’-diphosphate 
of dFdCyd; dFdCTP, 5’-triphosphate of dFdCyd; dATP, deoxyadenosine 
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ROLE OF p53R2 IN RADIOSENSITIZATION WITH dFdCyd 
 
Summary 
     Ribonucleotide reductase is a tetrameric protein consisting of two regulatory 
subunits (R1) and two catalytic subunits (R2).  Expression of R1 is constant 
throughout the cell cycle, whereas R2 is expressed primarily in S-phase.  
Recently, a novel ribonucleotide reductase gene, p53R2, was discovered.  
p53R2 is a homologue of the ribonucleotide reductase R2 subunit, and it was 
shown to be induced in a p53-dependent fashion following DNA damage by 
ionizing radiation with a concomitant decrease in R2.  However, little is known 
about the effect of RR inhibitors on p53R2 expression.  In particular, we wished 
to evaluate the effect of 2’,2’-difluoro-2’-deoxycytidine (dFdCyd), a nucleoside 
analog that can inhibit RR and be incorporated into DNA, on p53R2 expression.  
MCF-7 cells were incubated for 24 hr with dFdCyd at the IC10, IC50 or IC90 or 
treated with 5 Gy radiation, and then evaluated for expression of p53, p53R2 and 
R2 by Western blot analysis and cell cycle distribution by dual parameter flow 
cytometry.  p53R2 was expressed within 4 hr after dFdCyd addition at the IC10, 
IC50 or IC90 or after irradiation with 5 Gy and persisted for at least 72 hr.  
Exposure to dFdCyd resulted in an increase in S-phase content and an increase 
in R2 expression, whereas exposure to ionizing radiation resulted in a decrease 
in S-phase content and downregulation of R2.  We also wanted to evaluate
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whether p53R2 expression altered dNTP depletion and radiosensitization in wt 
p53 cell lines compared to their p53-deficient counterparts.  Although p53R2 was 
induced within 2 hr of dFdCyd exposure in wt p53 cell lines, dATP depletion and 
radiosensitization were similar to that seen in p53-deficient cell lines.  Taken 
together, these results suggest that p53R2 and R2 can be expressed 
simultaneously, and that p53R2 induction does not alter dNTP depletion in 
response to dFdCyd exposure. 
Introduction 
     Gemcitabine (dFdCyd, 2’, 2’-difluoro-2’-deoxycytidine) is a nucleoside analog 
with activity against a wide variety of malignancies, including pancreatic 1,2 and 
non-small cell lung cancers 3-5.  dFdCyd has shown excellent activity both in vitro 
and in vivo, either as a single agent or in combination with other drugs such as 
cisplatin 6 and docetaxel 7.  In addition, many preclinical studies have revealed 
the ability of dFdCyd to sensitize cultured cells to the effects of radiation, a 
process known as radiosensitization 8-11.  Clinical studies indicate that this 
radiosensitizing effect can be observed in vivo as well 12-17.   
     While the radiosensitizing property of dFdCyd has been demonstrated in 
many different in vitro and in vivo studies, the mechanism by which this occurs 
has remained elusive.  Distinguishing it from other radiosensitizers, dFdCyd does 
not enhance radiation-induced damage or alter the rate of repair 18,19. Two major 
biologic effects occur with dFdCyd.  Following intracellular phosphorylation, the 
diphosphate (dFdCDP) is a potent inhibitor of ribonucleotide reductase, the rate-
limiting enzyme in the de novo biosynthesis of deoxynucleotides 20,21.  This 
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inhibition results in depletion of dNTP pools, particularly dATP, and inhibition of 
DNA synthesis 8,11.   The triphosphate (dFdCTP) is incorporated into DNA, and it 
is thought that this effect contributes to the majority of the cytotoxicity observed 
with dFdCyd 22.  Previous studies by this and other labs have shown that dATP 
depletion 11,23,24 and S-phase accumulation prior to irradiation correlate strongly 
with radiosensitization 8,11,18.   
     Ribonucleotide reductase is responsible for the conversion of ribonucleotide 
diphosphates (rNDPs) to their corresponding deoxyribonucleotide diphosphates 
(dNDPs) through radical-based chemistry, providing a balanced supply of 
precursors for both DNA synthesis and repair 25,26.  Ribonucleotide reductase 
exists as a heterotetramer (α2β2) comprised of two catalytic subunits (R1) and 
two regulatory subunits (R2).  Recently a p53-inducible RR subunit, p53R2, was 
discovered, and it has been shown to be activated following DNA damage 
caused by exposure to ultraviolet or ionizing radiation, or cytotoxic concentrations 
of certain drugs 27.  p53R2 has high sequence homology with R2 except in the 
NH2-terminal region, and this difference has been postulated to be of regulatory 
importance 27.  Studies have demonstrated that p53R2 can bind with R1 to form 
an active heterotetramer 28. The appearance of p53R2 following induction of p53 
may be due in part to redistribution, since previous studies have shown that 
p53R2 is bound to p53 in undamaged cells and released following DNA damage 
29.  p53R2 has also been proposed to have a role in development, as p53R2-null 
mice have several developmental deficiencies, and die within 14 weeks post-birth 
due to renal failure 30.   
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 In view of the important role for ribonucleotide reductase in 
radiosensitization with dFdCyd, we wished to determine whether p53R2 affected 
this process.  We and others have demonstrated that dFdCyd, at concentrations 
>IC50, induces wild-type p53 expression.  While it may be presumed that 
induction of p53 by dFdCyd was accompanied by induction of p53R2 at the IC50, 
p53R2 expression was not measured.  In addition, it is not clear whether the low 
amount of p53 expression at the IC10 would be sufficient to induce p53R2.  We 
also wanted to evaluate if induction of p53R2 resulted in decreased dATP 
depletion and decreased radiosensitization in wt p53 cell lines compared to p53-
deficient cell types.  Preliminary accounts of a portion of these findings have 
been presented previously in abstract form 31,32. 
Materials and Methods 
Cell Culture and Drug Preparation.   The MCF-7 and MCF-7/Adr breast 
carcinoma cells were cultured in RPMI medium (GIBCO Laboratories, Grand 
Island, NY), supplemented with 10% calf serum (GIBCO), and 2 mM L-glutamine 
(Fisher Scientific, Fair Lawn, NJ).  The HCT116 and HCT116 p53-/- colon 
carcinoma cells were cultured in Dulbecco’s Modified Eagle Medium (GIBCO), 
supplemented with 10% fetal bovine serum (GIBCO), and 2mM L-glutamine 
(Fisher Scientific).  Cells were maintained in logarithmic growth as a monolayer 
in T-75 culture flasks at 37°C in a humidified atmo sphere containing 5% CO2.  
Gemcitabine was a generous gift from Eli Lilly and Co. (Indianapolis, IN), which 
was dissolved in PBS to obtain a stock solution of 10 mM and sterilized before 
diluting further with PBS to achieve final concentrations of 1, 10, and 100 µM. 
 66 
Irradiation of Cells.   Monolayer cultures of cells were irradiated using Co60 
(AECL Theratron 80) at 1-2 Gy/min.  Dosimetry was carried out using an ionizing 
chamber connected to an electrometer system that was directly traceable to a 
National Institute of Standards and Technology standard.  All cells were 
irradiated at room temperature. 
Flow Cytometry Analysis.  Control or drug-treated and/or irradiated cells were 
incubated in the dark with 30 µM bromodeoxyuridine (BrdUrd) for 15 minutes 
prior to the conclusion of the incubation period or for 15 minutes prior to 
irradiation, and processed as described previously 33.   
Western Blot Analysis.   After harvesting, lysis, and collection, the supernatant 
was used for analysis after determination of protein concentration with a Bio-Rad 
(Bio-Rad Laboratories, Hercules, CA) protein assay.  After electrophoresis for 2 
hours at 150 V, the protein was transferred onto Immobilon-P transfer membrane 
(Millipore Corp., Bedford, MA) for 2 hours at 125 mA.  After overnight blocking, 
the membrane was then incubated with a 1:1000 dilution of either p53R2 (Santa 
Cruz Biotechnology, Santa Cruz, CA) monoclonal goat, R2 (Santa Cruz) 
monoclonal goat, p53 (Ab-6) monoclonal mouse (Calbiochem), or Actin IgG 
antibody (Calbiochem) for 2 hours followed by incubation with a 1:10000 dilution 
of the corresponding secondary IgG horseradish peroxidase linked antibody for 1 
hour at room temperature.  After washing, proteins that bound the antibodies 
were visualized using an enhanced chemiluminescence detection system 
(Pierce, Rockford, IL). 
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Nucleotide Pool Analysis.   Cellular nucleotides were assayed as described 
previously 11.  Briefly, cells were harvested by trypsinization and nucleotides were 
extracted using 0.4 N perchloric acid.  Neutralized extracts were stored at –20°C 
until analysis.  Ribonucleotides were removed from the extracts using a boronate 
affinity column 34.  Cellular dNTPs and dFdCTP were separated and quantified by 
strong anion exchange HPLC using a Waters Alliance (Milford, MA) gradient 
system equipped with a photodiode array detector and controlled by Millennium 
2010 software.  Samples were loaded onto a Partisphere 4.6x250 mm strong 
anion exchange column (Whatman, Hillshore, OR) and nucleotides were eluted 
at 2 ml/min with a linear gradient of ammonium phosphate buffer ranging in 
concentration from 0.15 M (pH 2.8) to 0.60 M (pH 2.8).  Nucleotides were 
identified on the basis of their UV absorbance spectrum and quantified at either 
254 or 281 nm by comparison to the absorbance of a known amount of authentic 
standard.  All nucleotide pool measurements represent the average of at least 
four determinations except for the 16 hour point (duplicate determinations). 
Cell Survival Assay.  After treatment with dFdCyd and/or ionizing irradiation, 
cells were plated in 6-well dishes and allowed to grow for 10-14 days and 
colonies were stained with crystal violet.  Cell survival was expressed as a 
percentage of the control survival, after correcting for plating efficiency.  
Radiation survival data from dFdCyd-treated cells were corrected for plating 
efficiency using an unirradiated plate treated with dFdCyd under the same 
conditions.  Cell survival curves were fit using a linear-quadratic equation 35.  
Radiation sensitivity is expressed in terms of the mean inactivation dose, which 
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represents the area under the cell survival curve.   Radiosensitization is 
expressed as an enhancement ratio, which is defined as the mean inactivation 
dose (control)/mean inactivation dose (dFdCyd). 
Results 
Cell cycle distribution and protein expression following exposure to dFdCyd 
 We wished to determine whether induction of p53 by dFdCyd resulted in 
expression of p53R2, and the relationship to R2. Since R2 is a cell cycle-
regulated protein and dFdCyd produces an S-phase block, we also determined 
cell cycle position at each time point.  Consistent with our previous results 36, 
dFdCyd produced an S-phase block resulting in accumulation of 73%, 80% and 
85% of viable cells in S-phase by 24 hr after addition of the IC10, IC50 and IC90, 
respectively (Fig 3.1).  Following drug washout, the S-phase population declined 
at the IC10 and IC50, achieving control values or lower within 24 – 36 hr, 
respectively (Figs. 3.1A, 3.1B).  At the IC90 for dFdCyd (Fig 3.1C), S-phase 
content remained elevated for 24 hr post-washout but declined to 16% by 36 hr.   
     Western blot analysis demonstrated that exposure to IC10 dFdCyd resulted in 
a low but noticeable increase in p53 expression within 2 hr after drug addition 
(Fig. 3.2A).  Expression of p53R2 was apparent within 4 – 6 hr after drug 
addition, and it continued to increase over the 24 hr drug incubation period.  At 
the IC50 and IC90 for dFdCyd, expression of p53 and subsequently p53R2 was 
more rapid and intense (Figs. 3.2B, 3.2C).  Expression of R2 also increased 
during the drug incubation period for each dFdCyd concentration tested.   
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Figure 3.1.   Cell Cycle Distribution Following Exposure to dFdCy d.  MCF-7 
cells were exposed to A) IC10, B) IC50, or C) IC90 dFdCyd for up to 24 hr, 
harvested and processed for flow cytometry at times indicated as stated in 
“Materials and Methods.”  Drug was removed after 24 hr, and measurements 










Figure 3.2.   Protein Expression Following Exposure to dFdCyd.   MCF-7 cells 
were exposed to A) IC10, B) IC50, or C) IC90 dFdCyd for up to 24 hr, harvested 
and processed for western blotting at times indicated as stated in “Materials and 
Methods.”  Actin was used as a loading control.   
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Following dFdCyd washout, there was a substantial decrease in p53 expression 
by 48 hr at the IC10 and IC50 (Figs. 3.2A, 3.2B), whereas p53 remained elevated 
after washout of the IC90 (Fig 3.2C).  However, no decreases were observed in 
the expression of p53R2 after drug washout, as its expression was increased for 
at least 48 hr post-washout at all three concentrations of dFdCyd tested.    R2 
expression was apparent at 12 hr post-washout but decreased at later timepoints 
at the IC10, IC50 and IC90 for dFdCyd (Fig 3.2).   
Protein expression and cell cycle distribution following exposure to ionizing 
radiation 
     Following exposure of cells to 5 Gy ionizing radiation resulted in cells cycling 
out of S-phase and accumulating primarily in G1 and to a lesser extent in G2/M.  
By 6 hr post-irradiation, the S-phase fraction began to decrease from its initial 
level of approximately 35% (Fig 3.3).  This change was accompanied by a 
transient increase in G2/M.  The number of cells in G1 increased within 8 hr post-
irradiation, and >85% of the cells remained in G1 through 60 hr.  A moderate 
increase in S-phase cells (24%) at 72 hr post-irradiation indicated that cells were 
beginning to recover from irradiation.  The G1 block is consistent with intact 
radiation-induced cell cycle checkpoints.  Irradiation of MCF-7 cells with 5 Gy 
resulted in rapid and strong expression of p53 and p53R2 (Fig 3.4).  Both 
proteins were expressed for at least 60 hr post-irradiation.  In contrast, R2 
expression was highest at 0 hr, became undetectable by 6 hr post-irradiation and 
was not visible again up to 72 hr post-irradiation.  As expected for an S-phase  
 72 
 
Figure 3.3.   Cell Cycle Distribution Following Exposure to dFdCy d.  MCF-7 
cells were exposed to 5 Gy ionizing radiation, harvested and processed for flow 
cytometry at times indicated as stated in “Materials and Methods.”   
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Figure 3.4.   Protein Expression Following Exposure to dFdCyd.   MCF-7 cells 
were exposed to 5 Gy ionizing radiation, harvested and processed for western 
blotting at times indicated as stated in “Materials and Methods.”  Actin was used 
as a loading control.   
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specific protein, this expression pattern for R2 corresponded to the change in cell 
cycle distribution.   
Cell cycle distribution and protein expression following exposure to dFdCyd and 
radiation 
     In response to dFdCyd exposure, cells accumulated in S-phase, with 
approximately 25 % of cells remaining in G1 and G2/M at 24 hr dFdCyd 
exposure (Fig 3.5).  After irradiation, the cell cycle appeared similar to that with 
radiation alone in which there was an increase in G1 cells within 24-48 hr after 
irradiation.  Incubation of cells with dFdCyd at the IC10, IC50 or IC90 for 24 hr 
followed by 5 Gy irradiation produced increases in p53 and p53R2 expression 
(Fig 3.6).  While p53 appeared to decrease by 72 hr post-drug incubation and 
irradiation, p53R2 expression remained elevated for at least 72 hr.  R2 
expression increased during drug incubation as cells accumulated in S-phase, 
but decreases in R2 were observed by 36 hr post drug incubation and irradiation 
at all dFdCyd concentrations evaluated.    The block of cells in G1 was 
maintained through 72 hr post-irradiation, while S-phase content remained 
depressed during this time.   
p53R2 expression in matched cell lines 
     p53R2 expression was evaluated at the IC50 in two sets of cell lines matched 
for p53 status, MCF-7 (wt p53) and MCF-7/Adr (mt p53) breast cancer cells, and 
HCT116 (wt p53) and HCT116 p53-/- cells.  Similar to Fig 3.1, p53R2 expression 
was induced within 2 hr of exposure to dFdCyd (Fig 3.7).  Expression remained 
elevated for up to 24 hr of exposure.  Expression of p53R2 was also induced  
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Figure 3.5.   Cell Cycle Distribution Following Exposure to dFdCy d and 
Ionizing Radiation.  MCF-7 cells were exposed to A) IC10, B) IC50, or C) IC90 
dFdCyd followed by 5 Gy ionizing radiation, harvested and processed for flow 
cytometry at times indicated as stated in “Materials and Methods.”   
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Figure 3.6.   Protein Expression Following Exposure to dFdCyd and  Ionizing 
Radiation.  MCF-7 cells were exposed to A) IC10, B) IC50, or C) IC90 dFdCyd 
followed by 5 Gy ionizing radiation, harvested and processed for western blotting 





Figure 3.7.  p53R2 Expression in Cell Lines Matched  for p53 Status.   Breast 
and colon cancer cell lines matched for p53 status were exposed to IC50 dFdCyd 
for up to 24 hr and assayed for p53R2 expression by western blotting.  A341 lung 
cancer cells were used as a positive control for p53R2 expression. 
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within 2 hr of exposure to dFdCyd in the HCT116 cell line.  No expression of 
p53R2 was detected in the p53 deficient cell lines. 
dATP depletion  
     After determining that p53R2 could be induced in response to dFdCyd in wt 
p53 expressing cell lines, we next wanted to investigate whether induction of 
p53R2altered dATP depletion.  In response to IC10 dFdCyd, significant depletion 
of dATP is observed within 4 hr of dFdCyd exposure in both breast cancer cell 
lines (Fig 3.8A).  By 8 hr of exposure, both cell lines exhibited depletion of dATP 
to < 20% of control levels.  dATP levels had recovered some at 24 hr of 
exposure; however, the rebound effect was greater in the wt p53 cell line.  
Exposure of the breast cancer cell lines to IC50 dFdCyd resulted in a more rapid 
depletion of dATP.  By 4 hr of exposure, dATP was depleted to approximately 
10% of control values, and was near undetectable levels by 8 hr of exposure (Fig 
3.8B).  dATP remained depleted for the remainder of the 24 hr exposure.  dATP 
was also rapidly depleted in HCT116 cells after exposure to IC50 dFdCyd.  By 4 
hr of exposure, dATP had reached undetectable levels, and remained depleted 
for the remainder of the exposure (Fig 3.8C).  dATP was depleted much more 
slowly in the HCT116 p53-/- cell line, most likely due to slower accumulation of 
dFdCyd metabolites (data not shown).  
Cytotoxicity and Radiosensitization 
     After determining that p53R2 was induced in response to dFdCyd in wild-type 
p53 cell lines but dATP depletion was not affected, we next wanted to examine if 
p53R2 induction altered cytotoxicity and radiosensitization.  The breast cancer  
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Figure 3.8.  dATP depletion in response to dFdCyd e xposure.   Breast cancer 
cells were exposed to A) IC10 or B) IC50 dFdCyd, or C) colorectal cell lines were 
exposed to IC50 dFdCyd for up to 24 hr, and dATP levels were measured as 
described in “Materials and Methods.” 
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Table 3.1.  Cytotoxicity and Radiosensitization in Breast and Colon Cancer 
Cell Lines.  Breast and colon cancer cells were assayed for cytotoxicity and 
radiosensitization as described in “Materials and Methods.” 
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cell lines demonstrated similar sensitivities to dFdCyd as determined by the IC10 
and IC50 (Table 3.1).  However, MCF-7/Adr cells were less sensitive to radiation 
as determined by D-bar.  Both cell lines exhibited excellent radiosensitization at 
the IC10 and IC50, with radiation enhancement rations >1.6.   
     HCT116 cells were much more sensitive to dFdCyd compared to their p53 
deficient counterparts.  This again is probably due to the slower and lowered 
accumulation of dFdCyd metabolites in HCT116 p53-/- cells.  HCT116 p53-/- cells 
were slightly more sensitive to ionizing radiation.  Despite differences in 
sensitivity to dFdCyd and ionizing radiation when given alone, these cell lines 
exhibited a similar radiosensitization profile.  Both colon cancer cell lines were 
only radiosensitized at > IC50 dFdCyd concentrations.  
Discussion 
     p53R2 is a novel homologue of the ribonucleotide reductase subunit R2 that 
is activated via p53 following DNA damage.  p53R2 combines with R1 to form an 
active holoenzyme, and it has been proposed that this activation results in 
deoxynucleotide production for DNA repair 37.  It is likely that R1 is constitutively 
active so that it can form an active RR with p53R2 to provide dNTPs in any 
phase of the cell cycle, whereas R1 and R2 form the holoenzyme only active in 
S-phase.  While p53R2 can be expressed in any cell cycle phase, R2 is activated 
in an S-phase dependent fashion and is rapidly degraded following progression 
out of S-phase.  While previous studies demonstrated that expression of p53R2 
was rapidly induced following DNA damage from ionizing radiation 27, this is the 
first study that has extensively examined the kinetics of p53R2 and R2 
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expression in response to a chemotherapeutic agent, either alone or in 
combination with ionizing radiation.  Here we demonstrated that, after treating 
MCF-7 cells with dFdCyd which results in the accumulation of cells in S-phase, 
we were able to detect simultaneous expression of p53R2 and R2.  Our results 
indicate that p53R2 and R2 can be induced simultaneously in response to S-
phase directed agents.  Our results also suggest that p53R2 induction does not 
alter dATP depletion or radiosensitization in wt p53 cell lines compared to their 
p53-deficient counterparts.   
     We have extensively studied the kinetics of expression of the two small 
ribonucleotide reductase proteins under radiosensitizing conditions.  Surprisingly, 
we observed prolonged increases in p53R2 expression in response to non-
cytotoxic concentrations of dFdCyd.  p53R2 expression remained elevated for at 
least 48 hr post-washout, far longer than required for dNTP pools to stabilize.  
Expression of p53 R2 also remained elevated for at least 72 hr post-irradiation.  
This prolonged expression also was not dependent on p53, as p53 expression 
returned to control levels by 48 hr post-washout of low concentrations of dFdCyd.  
This finding implies that p53R2 may have other roles in the cell in addition to its 
role as a ribonucleotide reductase subunit.  A previous study by Thelander et al 
suggests that p53R2 is involved in the G1/S transition, as their study found that 
p53R2 expression peaked when cells were at the G1/S border 38.  It is tempting 
to speculate that p53R2 may also be involved in repair induced by these insults, 
but previous studies have demonstrated that most radiation-induced damage is 
repaired within 4 hr post-irradiation.   
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     Previous studies have demonstrated that, in wild-type p53 cells, both p53R2 
and R2 associate with p53 in resting cells 29.  Following exposure to DNA 
damaging agents such as UV, both subunits translocate from the cytoplasm to 
the nucleus and this movement results in increased ribonucleotide reductase 
activity.  We were able to detect increases in p53R2 expression within 4 hr after 
exposure to dFdCyd or ionizing radiation.  These findings support the hypothesis 
of translocation, as it is unlikely that a transcriptional mechanism would result in 
rapid increases in expression.  It is possible however that both translocation and 
transcription play a significant role in p53R2 upregulation.  An interesting and 
perhaps unexpected result was the longevity of p53R2 upregulation following 
DNA damage, as we were able to detect p53R2 expression for at least 72 hr 
after exposure to DNA damaging agents.  It is possible that early increases in 
p53R2 expression are due to translocation, and this activity is maintained via 
transcription. 
     Although p53R2 expression has been evaluated in a number of cell lines in 
response to DNA damage, very little work has been done to examine the exact 
effects of p53R2 expression on dNTP pools.  Here we have studied dATP 
depletion in response to dFdCyd exposure in cell lines matched for p53 status, 
and subsequently the ability to induce p53R2 after DNA damage.  Although 
p53R2 was induced within 2hr of dFdCyd exposure, dATP depletion was not 
altered in wt p53 cell lines compared to their p53-deficient counterparts.  This 
suggests that p53R2 does not contribute significantly to dNTP pools.  However, 
these cell lines have been cultured separately over a number of years and may 
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have acquired differences that altered cellular response to dFdCyd.  It is also 
possible that cell lines have intrinsic differences that also can affect cellular 
response.  It will be imperative to determine the exact role of p53R2 on 
maintaining dNTP pools in a single cell line. 
     By preparing samples for both western blotting and cell cycle analysis 
simultaneously, we have demonstrated that p53R2 and R2 can be induced 
simultaneously in response to a chemotherapeutic agent.  Also, the data indicate 
that R2 correlates with the level of S-phase accumulation, whereas p53R2 
expression is independent of cell cycle regulation.  Our results also demonstrate 
that expression of p53R2 does not affect sensitivity to dFdCyd either as a single 
agent or in combination with ionizing radiation.  This suggests that p53R2 activity 
does not significantly alter dNTP pools, as concluded by Thelander et al 38.  
However, it is also possible that, in specific cell types, that p53R2 activity 
contributes sufficiently to the maintenance of dNTP pools following exposure to 
dFdCyd to prevent radiosensitization, and this hypothesis is currently the subject 
of ongoing investigation in this laboratory.   
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Footnotes to Chapter III 
     1The footnotes used are: dFdCyd, 2’,2’-difluoro-2’-deoxycytidine; dCyd, 
deoxycytidine; dFdCMP, 5’-monophosphate of dFdCyd; dFdCDP, 5’-diphosphate 
of dFdCyd; dFdCTP, 5’-triphosphate of dFdCyd; dNTP, deoxynucleotide 
triphosphate; dATP, deoxyadenosine triphosphate, dCTP, deoxycytidine 
triphosphate; HPLC, high performance lipid chromatography; RR, ribonucleotide 
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p53R2 EXPRESSION IN RESPONSE TO dFdCyd EXPOSURE ACT S TO 
MAINTAIN dNTP POOLS AND ALTER RADIOSENSITIZATION 
 
Summary 
     Ribonucleotide reductase (RR) is a tetrameric protein consisting of two 
regulatory subunits (R1) and two catalytic subunits (R2).  Expression of R1 is 
constant throughout the cell cycle, whereas R2 is expressed primarily in S-
phase.  p53R2 is a homologue of the ribonucleotide reductase R2 subunit, and it 
was shown to be induced in a p53-dependent fashion following DNA damage by 
ionizing radiation and a few DNA-damaging drugs.  Previously, we evaluated the 
effects of p53R2 induction on dFdCyd-mediated dATP depletion and 
radiosensitization in cell lines matched for p53 status.  However, those cell lines 
have been cultured separately over a number of years and may have acquired 
differences that altered response to dFdCyd.  Therefore, it was imperative to 
evaluate the effects of p53R2 induction in a single cell line.  In A549 non-small 
cell lung cancer cells that were not radiosensitized at dFdCyd <IC50, siRNA-
mediated suppression of p53R2 produced excellent radiosensitization at the IC10.   
Silencing of p53R2 expression in A549 cells also resulted in increased depletion 
of dNTP pools in response to dFdCyd exposure.  Taken together, these results 
demonstrate that dFdCyd can induce p53R2 expression, and this expression 
may act to maintain dNTP pools.   
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Introduction 
     Gemcitabine (dFdCyd, 2’, 2’-difluoro-2’-deoxycytidine) is a nucleoside analog 
with activity against a wide variety of malignancies, including pancreatic (1, 2) 
and non-small cell lung cancer (3-5).  dFdCyd has shown excellent activity both 
in vitro and in vivo, either as a single agent or in combination with other drugs 
such as cisplatin (6) and docetaxel (7).  Several preclinical studies have 
demonstrated the ability of dFdCyd to sensitize cultured cells or tumor xenografts 
in animals to the effects of radiation, a process known as radiosensitization (8-
11).  Clinical studies indicate that this radiosensitizing effect can be observed in 
vivo as well (12-17).   
     While the radiosensitizing property of dFdCyd has been demonstrated in 
many different in vitro and in vivo studies, the mechanism by which this occurs 
has yet to be elucidated.  Most radiosensitizers work through either potentiation 
of radiation-induced DNA damage or through inhibition of its repair.   dFdCyd is 
unique in that it does not enhance radiation-induced DNA damage or alter the 
rate of repair (18, 19). Radiosensitization has been previously found to correlate 
with two processes.  Previous studies by this and other labs have shown that 
dATP depletion (20-22) and S-phase accumulation prior to irradiation correlate 
strongly with radiosensitization (23-25).   
     Recently a p53-inducible RR subunit, p53R2, was discovered, and it has been 
shown to be activated following DNA damage caused by exposure to ultraviolet 
or ionizing radiation, or cytotoxic concentrations of certain drugs (26).    p53R2 
has high sequence homology with R2 except in the NH2-terminal region, and this 
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difference has been postulated to be of regulatory importance (27).  Studies have 
demonstrated that p53R2 can bind with R1 to form an active heterotetramer (28).  
Previous studies have also demonstrated that p53R2, as well as R2, are 
regulated through interactions with wild-type p53 (29).  Studies in mice have 
demonstrated that p53R2 is essential in development, as p53R2-null mice die 
within 14 weeks after birth (30, 31).  In addition to its role in ribonucleotide 
reduction, p53R2 also has antioxidant (32) and metastasis-suppressing (33, 34) 
properties.  
     In view of the important role for ribonucleotide reductase in radiosensitization 
with dFdCyd, we wished to determine whether p53R2 affected this process.  
Previously, we have investigated induction of p53R2 following dFdCyd exposure, 
and found that p53R2 was induced in as little as 2 hr after dFdCyd addition.  In 
cell lines matched for p53, and subsequently p53R2, status, induction of p53R2 
did not affect dATP depletion or radiosensitization.  However, these cell lines 
displayed differences in sensitivity to either dFdCyd or ionizing radiation as single 
agents.  Also, these cell lines have been cultured separately over a number of 
years.  As a result, these cell lines may have acquired differences that altered 
cellular response to dFdCyd and/or radiation.  In order to more accurately 
examine the effects of p53R2 induction on dATP depletion and 
radiosensitization, we utilized siRNA-directed suppression of p53R2 expression 
to determine the contribution of this protein to cytotoxicity and radiosensitization 
with dFdCyd.  Preliminary accounts of a portion of these findings have been 
presented previously in abstract form (35). 
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Materials and Methods 
Cell Culture and Drug Preparation.   The MCF-7 breast carcinoma cell line was 
cultured in RPMI medium (GIBCO Laboratories, Grand Island, NY), 
supplemented with 10% calf serum (GIBCO), and 2 mM L-glutamine (Fisher 
Scientific, Fair Lawn, NJ).  The A549 lung carcinoma cell line was cultured in 
Dulbecco’s Modified Eagle Medium (GIBCO), supplemented with 10% fetal 
bovine serum (GIBCO), and 2mM L-glutamine (Fisher Scientific).  Cells were 
maintained in logarithmic growth as a monolayer in T-75 culture flasks at 37°C in 
a humidified atmosphere containing 5% CO2.  Gemcitabine was a generous gift 
from Eli Lilly and Co. (Indianapolis, IN), which was dissolved in PBS to obtain a 
stock solution of 10 mM and sterilized before diluting further with PBS to achieve 
final concentrations of 1, 10, and 100 µM. 
Irradiation of Cells.   Monolayer cultures of cells were irradiated using Co60 
(AECL Theratron 80) at 1-2 Gy/min.  Dosimetry was carried out using an ionizing 
chamber connected to an electrometer system that was directly traceable to a 
National Institute of Standards and Technology standard.  All cells were 
irradiated at room temperature. 
siRNA Silencing .  Cells are plated in 12-well dishes at a concentration of 
100,000 cells/well for each condition and allowed to grow for 48 hr.  Cells were 
then transfected with siRNA (Dharmacon, Lafayette, CO) using Lipofectamine 
(Gibco) for 24 hr.  Following this incubation, each well was washed and repleted 
with 1.5 ml media.  Cells were allowed to grow for another 48 hr then processed 
for Western blotting or clonogenic survival as described below.   
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Western Blot Analysis.  After harvesting, lysis, and collection, the supernatant 
was used for analysis after determination of protein concentration with a Bio-Rad 
(Bio-Rad Laboratories, Hercules, CA) protein assay.  After electrophoresis for 2 
hours at 150 V, the protein was transferred onto Immobilon-P transfer membrane 
(Millipore Corp., Bedford, MA) for 2 hours at 125 mA.  After overnight blocking, 
the membrane was then incubated with a 1:1000 dilution of either p53R2 (Santa 
Cruz Biotechnology, Santa Cruz, CA) monoclonal goat, R2 (Santa Cruz) 
monoclonal goat, p53 (Ab-6) monoclonal mouse (Calbiochem), or Actin IgG 
antibody (Calbiochem) for 2 hours followed by incubation with a 1:10000 dilution 
of the corresponding secondary IgG horseradish peroxidase linked antibody for 1 
hour at room temperature.  After washing, proteins that bound the antibodies 
were visualized using an enhanced chemiluminescence detection system 
(Pierce, Rockford, IL). 
Cell Survival Assay .  After treatment with dFdCyd and/or ionizing irradiation, 
cells were plated in 6-well dishes and allowed to grow for 10-14 days and 
colonies were stained with crystal violet.  Cell survival was expressed as a 
percentage of the control survival, after correcting for plating efficiency.  
Radiation survival data from dFdCyd-treated cells were corrected for plating 
efficiency using an unirradiated plate treated with dFdCyd under the same 
conditions.  Cell survival curves were fit using a linear-quadratic equation (36).  
Radiation sensitivity is expressed in terms of the mean inactivation dose, which 
represents the area under the cell survival curve.   Radiosensitization is 
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expressed as an enhancement ratio, which is defined as the mean inactivation 
dose (control)/mean inactivation dose (dFdCyd). 
Nucleotide Pool Analysis.   Cellular nucleotides were assayed as described 
previously (37).  Briefly, cells were harvested by trypsinization and nucleotides 
were extracted using 0.4 N perchloric acid.  Neutralized extracts were stored at –
20°C until analysis.  Ribonucleotides were removed from the extracts using a 
boronate affinity column (38).  Cellular dNTPs and dFdCTP were separated and 
quantified by strong anion exchange HPLC using a Waters Alliance (Milford, MA) 
gradient system equipped with a photodiode array detector and controlled by 
Millennium 2010 software.  Samples were loaded onto a Partisphere 4.6x250 
mm strong anion exchange column (Whatman, Hillshore, OR) and nucleotides 
were eluted at 2 ml/min with a linear gradient of ammonium phosphate buffer 
ranging in concentration from 0.15 M (pH 2.8) to 0.60 M (pH 2.8).  Nucleotides 
were identified on the basis of their UV absorbance spectrum and quantified at 
either 254 or 281 nm by comparison to the absorbance of a known amount of 
authentic standard.  All nucleotide pool measurements represent the average of 
at least four determinations except for the 16 hour point (duplicate 
determinations). 
Results 
SiRNA Silencing of p53R2 Expression in MCF-7 Cells 
     The previous studies demonstrated that, even at the IC10 for dFdCyd, p53 and 
p53R2 could be induced.  With the prolonged expression of p53R2 for several 
days following drug and radiation treatment, it seemed possible that p53R2 might 
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elevate the dATP pools sufficiently to thus lessen radiosensitization with dFdCyd.   
Thus, we wished to determine whether decreasing the expression of p53R2 
would prevent radiosensitization with dFdCyd.  To accomplish this, MCF-7 cells 
were transfected with siRNA for p53R2 for 24 hr, then allowed to grow for various 
lengths of time before dFdCyd addition to determine the optimal timecourse for 
p53R2 suppression. Subsequent silencing of dFdCyd-mediated p53R2 
expression was measured using Western blotting.  dFdCyd-mediated p53R2 
expression was inhibited by siRNA when cells were exposed to dFdCyd 24 hr 
post transfection (Fig 4.1A).  Maximal inhibition of p53R2 expression was 
observed when cells were exposed to dFdCyd 48 hr post transfection, and 
p53R2 expression in response to dFdCyd was inhibited for at least another 48 hr.  
This was a specific response, since a non-specific siRNA sequence or siRNA for 
lamin did not alter p53R2 expression.  At the time of maximal inhibition of p53R2 
expression, expression of R2 and p53 were unaffected, demonstrating the 
specificity of the siRNA sequence and silencing technique (Fig 4.1B).   
Cytotoxicity and Radiosensitization in MCF-7 Cells Following Suppression of 
p53R2   
     After determining conditions under which siRNA could effectively inhibit 
p53R2 expression in response to dFdCyd exposure, the effects of this inhibition 
on dFdCyd sensitivity were evaluated.  At 48 hr post-transfection, cells were 
exposed to a range of concentrations of 3 nM to 300 nM of dFdCyd for 24 hr, and 
cytotoxicity was evaluated using a colony-formation assay.  Cells untreated with 
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siRNA demonstrated dose-dependent sensitivity to dFdCyd, with an observed 
IC50 of 55 nM (Fig 4.2A).  Pretreatment with siRNA for p53R2 did not decrease  
sensitivity to dFdCyd (IC50 = 55 nM).  Cells treated with non-specific siRNA 
demonstrated similar sensitivity to dFdCyd (IC50 = 70 nM).  Western blot analysis 
indicated that p53R2 expression was significantly suppressed using siRNA (Fig 
4.2B).  Thus, inhibition of p53R2 expression did not alter sensitivity to dFdCyd in 
the MCF-7 cells.   
     Since radiosensitization of MCF-7 cells with dFdCyd does not depend upon 
cytotoxicity, the effect of siRNA suppression of p53R2 on radiation sensitization 
was determined.  At 48 hr post-transfection, cells were incubated for 24 hr with 
dFdCyd at the IC10 followed by irradiation.  MCF-7 cells not treated with siRNA 
were radiosensitized by IC10 (10 nM) dFdCyd, with an observed radiation 
enhancement ratio (RER) of 1.7+0.3 (Fig 4.3, Table 4.1).  After 72 hr of exposure 
to siRNA for p53R2, dFdCyd-mediated radiosensitization was not enhanced, as 
the observed RER was 1.8+0.3.  Treatment with a non-specific siRNA sequence 
for 72 hr also did not significantly alter dFdCyd-mediated radiosensitization, as 
the RER was 1.5+0.2.  Western blot analysis indicated substantial silencing of 
p53R2 expression in response to dFdCyd. 
siRNA Silencing of p53R2 in the A549 Cell Line 
     After determining that p53R2 status did not appear to alter radiosensitization 
in a cell line that was already highly radiosensitized by dFdCyd, we then wanted 
to examine the effects of p53R2 expression in a cell line that was not  
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Figure 4.1.  siRNA Suppression of dFdCyd-Mediated p 53R2 Expression.  
MCF-7 cells were treated to an siRNA transfection mixture for 24 hr.  At various 
timepoints thereafter, cells were exposed to dFdCyd for 24 hr and assayed for 
protein expression by western blotting as described in “Materials and Methods”.  
Actin was used as a loading control. 
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Figure 4.2.  dFdCyd-Mediated Cytotoxicity Following  siRNA Suppression of 
p53R2.  A) MCF-7 cells were transfected for 24 hr, then allowed to grow for 48 
hr.  Cells were then exposed to 3nm-300nm dFdCyd for 24 hr, and evaluated for 
cell survival as described in “Materials and Methods”.  B) Suppression of p53R2 





Figure 4.3.   Radiosensitization in MCF-7 Cells Following Suppres sion of 
p53R2.  In MCF-7 cells either A) not transfected, B)transfected with p53R2 
siRNA, or C) transfected with non-specific siRNA, dFdCyd-mediated 
radiosensitization is evaluated.  D) p53R2 silencing is confirmed using western 

















Table 4.1.  dFdCyd-mediated Cytotoxicity and Radios ensitization Following 
siRNA Transfection in MCF-7 Cells.  In MCF-7 breast cancer cells either not 
transfected, or transfected with p53R2 or non-specific siRNA, cytotoxicity, 










radiosensitized by dFdCyd at non-cytotoxic concentrations.  In previous work, the 
A549 lung carcinoma (wild-type p53) cell line exhibited little to no 
radiosensitization with< IC50 dFdCyd (non-published findings).  p53R2 
expression also had not been previously examined in this cell line.  Western blot 
analysis indicated that p53R2 was maintained at low levels in unstressed A549 
cells, and induced within 24 hr of IC10 dFdCyd addition (Fig. 4.4).  Similar to 
findings in the MCF-7 cell line, expression of p53R2 remained elevated for at 
least 96 hr post-washout.  Using siRNA technology, we were able to effectively 
silence dFdCyd-mediated increases in p53R2 expression (Fig. 4.4).  To 
characterize p53R2 silencing, A549 cells were transfected for 24 hr, and allowed 
to grow for various lengths of time before a 24 hr exposure to dFdCyd.  dFdCyd-
mediated p53R2 expression was completely suppressed for at least 120 hr post 
transfection.  
Cytotoxicity and Radiosensitization in the A549 Cell Line Following p53R2 
Silencing 
     After determining that we could effectively silence increases in p53R2 
expression in response to dFdCyd exposure in A549 cells, we next wanted to 
examine the effects of this silencing on dFdCyd-mediated cytotoxicity and 
radiosensitization.  Similar to previous experiments in MCF-7 cells, cells were 
treated with dFdCyd 48 hr post-transfection and assayed for cell survival.  
Although p53R2 expression was significantly suppressed, no effect on dFdCyd 
cytotoxicity was observed (Fig. 4.5).  Cells not treated with siRNA demonstrated 
dose-dependent sensitivity to dFdCyd, with an IC10 and IC50 of 10nM and 45 nM,  
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Figure 4.4.  Silencing of p53R2 Expression in A549 Cells.   A) p53R2 
expression was evaluated in unstressed cells.  B) p53R2 expression was 
evaluated in response to a 24 hr exposure to IC10 dFdCyd.  C) Silencing of 
p53R2 expression was evaluated.  Cells were exposed to the transfection 
mixture for 24 hr then allowed to grow for another 48 hr.  Cells were then 
exposed to IC10 dFdCyd for 24 hr, then harvested at the times indicated and 
assayed for p53R2 expression.  24D indicates a 24 hr exposure to dFdCyd, and 
MT indicates a mock transfection, consisting of a 24 hr exposure to the 
transfection mixture without siRNA, and dFdCyd exposure 48 hr after 
transfection.   
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Figure 4.5.   Cytotoxicity in A549 Cells Following Silencing of p 53R2.  A) 
dFdCyd- mediated cytotoxicity was evaluated following siRNA silencing of 
p53R2.  Cells were transfected for 24 hr, then allowed to grow for 48 hr.  Cells 
were then exposed to dFdCyd for 24 hr and assayed for cell survival.  B) siRNA 
silencing of p53R2 was assayed using western blotting. 
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respectively.  Following suppression of p53R2, dFdCyd sensitivity was slightly 
but not significantly decreased at higher dFdCyd concentrations.  Pretreatment 
with non-specific siRNA did not change dFdCyd sensitivity from that observed in 
cells not treated with siRNA.   
     We next evaluated the effects of p53R2 silencing on radiosensitization in 
A549 cells.  After 48 hr post-transfection, A549 cells were treated with IC10 
dFdCyd for 24 hr followed by 5 Gy irradiation.  Cells that were not pretreated with 
siRNA were marginally radiosensitized, with a RER of 1.3+0.1 (Fig 4.6).  
Following silencing of p53R2, radiosensitization was increased, with an observed 
RER of 1.8+0.1.  Radiosensitization was not altered when cells were pretreated 
with non-specific siRNA, with an observed RER of 1.3 + 0.1.   
DNTP Pools Following p53R2 Suppression 
     After observing that p53R2 silencing increased radiosensitization in A549 
cells, we next wanted to determine if this was the result of greater dATP 
depletion in response to dFdCyd exposure.  In previous studies, dATP was 
depleted to about 35% of control levels in response to IC10 dFdCyd (unpublished 
results).  At 48 hr post-transfection, A549 cells were treated with dFdCyd for up 
to 24 hr, and dNTP pool levels were measured.  In untransfected cells, dATP 
was depleted to approximately 35% of control levels, at 4 hr of dFdCyd exposure 
(Fig 4.7A).  dATP levels recovered at 24 hr of exposure to near control levels.  
Following suppression of p53R2, dATP levels were depleted to nearly 10% of 




Figure 4.6.   dFdCyd-Mediated Radiosensitization Following Suppre ssion of 
p53R2 Expression.  Radiosensitization was assayed in A549 cells that were 
either A)untransfected, B)transfected with p53R2 siRNA, or C) transfected with 
non-specific siRNA, as described in “Materials and Methods”.  D) Silencing of 
p53R2 was confirmed using western blotting.  Figures A-C are representative of 
an experiment that was performed at least three times. 
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Table 4.2.  dFdCyd-mediated Cytotoxicity and Radios ensitization Following 
siRNA Transfection in A549 Cells.  In A549 lung cancer cells either not 
transfected, or transfected with p53R2 or non-specific siRNA, cytotoxicity, 











maintained at 24 hr of exposure.  Following transfection with non-specific siRNA, 
dATP depletion was similar to that observed in untransfected cells.   
     Furthermore, following suppression of p53R2 expression, dGTP, TTP, and 
dCTP were depleted in response to dFdCyd.  Conversely, in untransfected cells 
or cells treated with non-specific siRNA, dNTPs were not significantly depleted 
(Fig 4.7).  TTP levels were 200% of control levels at 24 hr of dFdCyd exposure, 
compared to 30% in cells in which p53R2 had been silenced.  While dCTP and 
dGTP were depleted in cells treated with p53R2 siRNA, the levels of these 
dNTPs were at near control levels at 24 hr of dFdCyd exposure. 
Discussion 
     p53R2 is a p53-inducible homologue of the small subunit of ribonucleotide 
reductase, and it has been proposed to be activated in response to DNA damage 
to provide dNTPs for DNA repair (39).  Previous research has demonstrated that 
p53R2 can pair with R1 and produce ribonucleotide reductase activity (40).  
Although much work has been dedicated to observing p53R2 expression and 
ribonucleotide reductase activity in response to radiation, little has been done to 
evaluate p53R2 expression in response to chemotherapeutics.  In particular, no 
study has examined the effects of p53R2 expression in response to 
chemotherapeutics on dNTP pool levels.  Here we have examined p53R2 
expression in response to dFdCyd on dNTP pool levels and radiosensitization 
through the use of siRNA silencing.  We have demonstrated that p53R2 
expression actively maintains dNTP pools in response to dFdCyd, and in certain 
cell lines this activity can decrease radiosensitization.   
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Figure 4.7.   dNTP pools depletion in response to dFdCyd Exposure .  In cells 
that were either untransfected (squares), transfected with p53R2 siRNA 
(triangles), or transfected with non-specific siRNA (upside down triangles), 
depletion of A) dATP, B) dGTP, C) TTP, or D) dCTP was evaluated.  p53R2 and 
R2 expression was evaluated using western blotting (inset). 
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     We examined the effects of p53R2 silencing on dFdCyd-mediated cytotoxicity 
in two wt p53 cell lines.  Suppression of p53R2 expression did not alter sensitivity 
to dFdCyd as a single agent in either cell line.  This finding contrasts with a 
previous study that reported that silencing of p53R2 increased the cytotoxic 
effects of 5-fluorouracil (41).  These differences may be attributable to the 
different targets of these two agents.  Another study found that the R1/p53R2 
pairing demonstrated differing sensitivities to ribonucleotide reductase inhibitors 
compared to the R1/R2 pairing in a cell free system (42).  In that study, the 
R1/p53R2 pairing was more sensitive to the iron chelator DFO, less sensitive to 
the radical scavenger hydroxyurea, and equally sensitive to triapine, which is an 
iron chelator and a radical scavenger, compared to the R1/R2 pairing.  It will be 
important to determine if the effects observed in a cell-free system will translate 
to intact cells, and if silencing of individual subunits can potentiate the cytotoxicity 
of these agents. 
    Although we did not observe an increase in dFdCyd-mediated 
radiosensitization in MCF-7 cells, radiosensitization was increased in A549 cells 
following p53R2 suppression.  We previously observed that exposure to dFdCyd 
resulted to dATP depletion in MCF-7 to near undetectable levels, although dATP 
levels recovered slightly at later timepoints (43), whereas exposure to dFdCyd in 
A549 cells only resulted in 65% depletion of dATP compared to untreated cells 
(unpublished results).  It is possible that, once the 80% threshold required for 
radiosensitization is reached, increased dATP depletion alone does not increase 
radiosensitization.  This is supported by the finding that increased dATP 
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depletion in MCF-7 cells, achieved by increasing dFdCyd concentration the IC10 
to the IC50, did not result in increased radiosensitization (44).  However, we also 
observed near complete p53R2 suppression in A549 cells, compared to 
approximately 70% suppression on p53R2 expression in MCF-7 cells.  It is also 
possible that this low level of p53R2 expression is sufficient to maintain dATP 
pools in response to dFdCyd, thus preventing increased radiosensitization.   
     In this study, we found that suppression of p53R2 resulted in increased dATP 
depletion in response to dFdCyd exposure compared to untransfected A549 
cells.  In addition, we also observed increased depletion of the other dNTPs.  
Previous studies have demonstrated that only dATP is significantly depleted in 
response to low concentrations of dFdCyd (45).  Here we have demonstrated 
that following suppression of p53R2, all dNTPs are depleted to < 40 % of control 
levels in response to dFdCyd exposure.  This strongly suggests that the activity 
of p53R2, not salvage pathways, is the major contributor in maintaining dNTPs in 
response to dFdCyd in wt p53 A549 cells.  In mt p53 cells, salvage pathways are 
likely the major contributor to maintenance of dNTPs following dFdCyd exposure.   
     The results indicate that p53R2 actively maintains dNTP pools in response to 
dFdCyd exposure in A549 cells, and this activity can decrease radiosensitization 
in certain cell lines.  As p53R2 suppression resulted in increased dATP depletion 
following dFdCyd exposure in A549 cells, it is possible that dFdCyd is a more 
potent inhibitor of R1/R2 compared to R1/p53R2.  However, it is also possible 
that dFdCDP did not accumulate to a high enough level to inhibit ribonucleotide 
reductase activity in A549 cells.  In either case, our findings suggest that p53R2 
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should be further evaluated as a target to manipulate in increasing 
radiosensitization with dFdCyd and other ribonucleotide reductase inhibitors.   
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Footnotes to Chapter IV 
 
     1The footnotes used are: dFdCyd, 2’,2’-difluoro-2’-deoxycytidine; dCyd, 
deoxycytidine; dFdCMP, 5’-monophosphate of dFdCyd; dFdCDP, 5’-diphosphate 
of dFdCyd; dFdCTP, 5’-triphosphate of dFdCyd; dNTP, deoxynucleotide 
triphosphate; dATP, deoxyadenosine triphosphate, dCTP, deoxycytidine 
triphosphate; TTP, thymidine triphosphate; dGTP, deoxyguanosine triphosphate; 
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     The major goal of this dissertation was to better understand the mechanisms 
by which dFdCyd potentiates radiation-induced cell killing.  Previous work has 
demonstrated that radiosensitization with dFdCyd correlated with dATP depletion 
1-3 and S-phase accumulation 3-5 prior to radiation exposure.  We evaluated the 
roles of p53, and p53R2, a ribonucleotide reductase small subunit homologue, in 
the radiosensitizing process.  Whereas previous studies focused on low 
concentrations of dFdCyd in radiosensitization 2, it was important to determine 
the effect of high, clinically relevant concentrations on induction of the cell cycle 
regulatory protein p53 and subsequent radiosensitization.  Studies in Chapter II 
demonstrated that although we were able to rapidly induce p53 expression in 
response to clinically relevant concentrations of dFdCyd, excellent 
radiosensitization was observed in MCF-7 cells.  As ribonucleotide reductase is a 
target of dFdCyd, it was a natural progression to investigate potential roles of 
p53R2, a newly discovered ribonucleotide reductase subunit, in our 
radiosensitizing model. Also the accumulated work in this area has not defined a 
role for p53 in dFdCyd-mediated radiosensitization 6.  Since p53 promotes both 
pathways of survival and cell death, the survival pathways could nullify the 
effects of the death pathways.  By targeting a component of the survival pathway, 
it may be possible to shift the effects of p53 toward cell death.  Previous studies 
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had reported a slow increase in p53R2 expression in response to large doses of 
ionizing radiation 6.  Therefore it was necessary to first determine if p53R2 would 
be induced by dFdCyd quickly enough to protect dNTP pools from depletion.  In 
Chapter III we evaluated the kinetics of p53R2 expression in response to dFdCyd 
and/or ionizing radiation and observed a dose-dependent effect on induction.  
However, induction of p53R2 did not affect dATP depletion or radiosensitization 
in cell lines isogenic for p53 status.  In Chapter IV we more closely evaluated the 
effects of p53R2 expression on radiosensitization by silencing p53R2 in MCF-7 
and A549 cells using siRNA.  We observed an increase in radiosensitization in 
A549 cells following silencing of p53R2, which corresponded to an increase in 
dATP depletion. 
     Much work has been dedicated to evaluating the effects of p53 on dFdCyd-
mediated cytotoxicity and radiosensitization 7-14.   In particular, work in D54 
glioblastoma cells appeared to indicate that p53 expression resulted in G1 
accumulation in response to dFdCyd, perhaps due to damaged cells progressing 
from S-phase into G2/M and ultimately G1.  This suggested that p53 could alter 
clinical response by preventing the S-phase accumulation necessary for 
radiosensitization.  Since tumors are generally a mixture of p53 wt and mt cells, 
this would be a major clinical issue.  Our work here confirmed the opposite, that 
clinically relevant concentrations of dFdCyd combined with ionizing radiation 
resulted in increased radiosensitization compared to lower dFdCyd 
concentrations in MCF-7 cells, a finding that bodes well for clinical outcome.  The 
D54 cell line has been unique in its resistance to radiosensitization.  Closer 
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examination of this cell line could provide information on which cellular 
characteristics result in resistance to dFdCyd-mediated radiosensitization, giving 
clinicians more tools to enhance clinical outcome.  Overall, the mounting 
evidence suggests that the effects of p53 on dFdCyd-mediated cytotoxicity and 
radiosensitization are cell line specific.   
     We initiated a study to closely examine the kinetics of p53R2 expression in 
response to a chemotherapeutic agent, either alone or in combination with 
radiation.   Interestingly, p53R2 expression was induced within 4 hr of dFdCyd 
addition in MCF-7 cells, even at low, non-cytotoxic concentrations.  Our lab has 
subsequently demonstrated that non-cytotoxic concentrations of dFdCyd can 
cause an increase in DNA damage or as measured by H2AX phosphorylation 
(Michael Im, unpublished results).  DNA damage as measured by 
phosphorylated H2AX returned to near-control levels within 6 hr after dFdCyd 
removal.  Previous work has demonstrated that most radiation-induced DNA 
damage is repaired within this time frame as well 15.  However, p53R2 expression 
remained elevated for at least 48 hr after drug removal and for at least 72 hr 
post-irradiation in the MCF-7 cell line, and data also indicated that p53R2 
remained elevated for at least 96 hr after dFdCyd washout in the A549 cell line.  
Our study also demonstrated that p53 expression returned to near control levels 
by 48 hr post-washout following exposure to low or moderate concentrations of 
dFdCyd, although expression of p53 remained elevated at this timepoint after 
exposure to IC90 dFdCyd or ionizing radiation in MCF-7 cells.  This begs the 
question, why does p53R2 expression remain elevated long after DNA damage 
 122 
is expected to have been repaired?  One possible answer is that p53R2, once 
activated, remains upregulated as a safeguard against future insults.  It is also 
possible that p53R2 remains upregulated due to the occurrence of secondary 
lesions that previous studies were not designed to detect such as persistent DNA 
mismatches.  One can also speculate that continued persistence of p53R2 
expression serves in signaling programmed cell death, although little to no cell 
death would be expected following exposure to IC10 dFdCyd.   
     Despite observing significant inhibition of p53R2 using siRNA silencing in both 
cell lines, we only observed an increase in radiosensitization in the A549 cell line.  
Our data indicate that silencing of p53R2 in A549 cells increases dFdCyd-
mediated radiosensitization as measured by an increase in the radiation 
enhancement ratio (RER) from 1.3 to 1.8.  A recent report by Yen et al has 
demonstrated that suppression of p53R2 results in depleted dNTP pools 16.  
However, in the MCF-7 cell line, we were not able to increase radiosensitization 
with dFdCyd by suppression of p53R2.  It has been long established that dFdCyd 
significantly alters dNTP pools, most importantly a drastic reduction in dATP 
levels in solid tumor cells, and this reduction of dATP correlates with 
radiosensitization 3,17.  In the MCF-7 cell line, it is likely that addition of dFdCyd 
results in dNTP depletion to such an extent that suppression of p53R2 has little 
added benefit to dFdCyd-mediated radiosensitization.  However, previous 
unpublished data from our lab indicates that addition of dFdCyd only results in a 
moderate decrease in dNTP pools in A549 cells.  Since we did not observe 
complete silencing of p53R2 in MCF-7 cells, it is possible that the remaining level 
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of p53R2 was sufficient to maintain dNTP pools in response to dFdCyd.  
However, previous work in our lab demonstrated no change in dFdCyd-mediated 
radiosensitization in MCF-7 cells at the IC50 compared to the IC10, despite a more 
rapid and complete depletion of dATP 13, suggesting that further suppression of 
p53R2 will likely not increase radiosensitization.  Western blot analysis also 
indicated two discrete bands corresponding to p53R2 in MCF-7 cells, opposed to 
a singular band in A549 cells.  It is possible that the second observed band in 
MCF-7 cells represents partially degraded p53R2 or a dominant negative version 
of this protein.  Either of these scenarios could presumably result in lowered 
p53R2 activity in this cell line, which is supported by increased dATP depletion 
observed in MCF-7 cells at the IC10 compared to A549 cells, a hypothesis 
requiring further laboratory investigation. 
     Our work here suggests that upregulation of p53R2 results in dNTP pool 
maintenance in A549 cells, in contrast to a report by Thelander et al suggesting 
that upregulation of p53R2 does not significantly alter dNTP pools following 
exposure to adriamycin or ultraviolet radiation 18.  However, that study reported a 
markedly slower and more modest increase in p53R2 expression than we 
observed.  The Thelander study utilized cells derived from normal tissues, and it 
is possible that p53R2 is induced at much lower levels in normal tissue compared 
to cancer cells.  These findings suggest that the role of p53R2 may shift once a 
tissue becomes cancerous, or perhaps play a role in tumorigenesis.  In this 
scenario, in normal tissues, p53R2 is maintained at low levels and acts primarily 
to maintain a basal level of dNTPs for DNA repair in non-cycling cells once 
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paired with R1.  Conversely, in cancerous tissues, p53R2 can be upregulated 
quickly to respond to chemotherapeutics and other insults that could result in 
tumor death if left unchecked, allowing for the continued progression of 
cancerous lesions.  This hypothesis is supported by a number of histological 
studies that found p53R2 to be undetectable in normal tissues, but increasingly 
expressed with increased tumor progression 19-21.  This scenario, while intriguing, 
would require further investigation to be confirmed.   
     The increasing research in this field indicates that p53R2 is an attractive 
target for gene manipulation in cancer therapy.  As previously mentioned, 
silencing of p53R2 does result in a moderate increase in 5-fluorouracil-mediated 
cytotoxicity 22.  Inhibition of p53R2 could result in both a decreased rate and 
fidelity of DNA repair after exposure to DNA damaging agents, due to 
perturbations in the dNTP pools.  The effects of p53R2 suppression are most 
likely to be of benefit with agents that create or potentiate oxidative stress, such 
as radiation and radiomimetics.  It has been previously demonstrated that 
p53R2-null mice die within 14 weeks post-birth due to kidney failure caused by 
oxidative stress 23,24, and p53R2 has been reported to possess antioxidant 
activity 25.  Silencing or suppression of p53R2 may increase the therapeutic 
benefits of these agents by increasing their cytotoxic potential within the tumor.  
As a result, these agents could be administered at lower doses, thereby 
diminishing death to normal tissue and improving the quality of life for patients.  It 
must be noted that we did not observe a difference in radiation sensitivity in our 
studies following suppression of p53R2.  However, our studies were designed to 
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achieve optimal silencing of p53R2 at the time of dFdCyd exposure.  A study in 
which p53R2 silencing was optimal at the time of irradiation could possibly 
produce a different result. 
     On the other hand, manipulation of p53R2 may not occur without cost.  
Recent studies have indicated that p53R2 prevents metastasis, counteracting the 
pro-metastatic properties of R2 26,27.  Long-term suppression of p53R2 in wt p53 
tumors may result in increased cytotoxicity locally, but produce deleterious 
effects globally.  However, p53R2 will remain an exciting gene therapy target, 
particularly in combination with current ribonucleotide reductase inhibitors that 
appear to inhibit R1/R2 more effectively than R1/p53R2.  Scientists and clinicians 
alike must move cautiously in investigation and incorporating this strategy into 
treatment.  
     In our studies, suppression of p53R2 led to increased radiosensitization in 
A549 cells.  However, other studies did not demonstrate a difference in 
radiosensitization when p53 was disrupted in other wt p53 cell lines 7,28.  Since 
p53R2 is directly induced by p53, it seems puzzling on the surface that disruption 
of p53 did not alter radiosensitization in the same manner as silencing of p53R2.  
Although those studies did not examine dNTP pool depletion, it is likely that 
dNTP pools were depleted in response to dFdCyd similarly following p53 
disruption as we observed following p53R2 silencing.  It is possible that, following 
disruption of p53, cells can accumulate DNA damage without being targeted for 
programmed cell death, thus leaving damaged cells free to propagate.   
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Figure 5.1.  Proposed Mechanism of dFdCyd-Mediated Radiosensitization.   
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Conversely, when p53R2 is inhibited in p53-expressing cells, p53 can induce 
programmed cell death and damaged cells are eliminated.   
     Much work in this laboratory and others has helped to form our current model 
of dFdCyd-mediated radiosensitization (Fig 5.1).  Following exposure to dFdCyd 
alone, the dFdCDP-mediated imbalance in dNTP pools will result in DNA 
mismatches.  Without further insults, most mismatches can be repaired and most 
cells can recover.  However, if ionizing radiation follows dFdCyd exposure, 
increased DNA damage in the face of depleted dNTP pools results in increased 
persisting mismatches which eventually become mutations, resulting in cell 
death.  This hypothesis is supported by previous studies in this laboratory 29.  In 
wt p53 cells, upregulation of p53R2 in response to dFdCyd and ionizing radiation 
may result in dNTP pool maintenance and fewer persisting mutations, thus 
reducing radiosensitization.  A future project in this laboratory will evaluate the 
effects of p53R2 silencing on mutation frequency in response to dFdCyd and 
radiation in an attempt to correlate these findings into a more comprehensive 
theory.  If our current hypothesis is correct, then silencing of p53R2 in A549 cells 
should result in increased mutation frequency to correspond to increased 
radiosensitization.      
     The discovery of p53R2 by Tanaka et al was considered a major development 
for the ribonucleotide reductase field, as it potentially answered the longstanding 
question of how dNTPs were produced for DNA repair outside of S-phase.  
Further research on this novel protein has uncovered new and unexpected roles, 
so it appears that p53R2 has an even greater role than initially anticipated.  As 
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we were able to increase dFdCyd-mediated radiosensitization through silencing 
of p53R2 in the A549 cell line, p53R2 appears to be an attractive target for gene 
manipulation for select treatments and cancer types.  This manipulation by no 
means should be viewed as a cure-all, and much work is still required in 
identifying both the treatments and cancer types that will benefit most from 
inhibition of p53R2.  As the field moves closer toward the individualization of 
cancer treatment, identifying targets such as p53R2 will be of great importance in 
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